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SUMMARY HJ III
Helicobacter pylori (H pylori) infection is the commonest chronic bacterial 
infection world-wide. The work carried out in this thesis has sought to explore 
the effect of the infection on gastric secretory function in man.
'Æ
i
W e developed a new test of gastric acid secretion using the substance
'gastrin releasing peptide (GRP) as the stimulus. Acid secretion measured in 
response to intravenous infusion of GRP reflects the combined functional
response of the antrum and body of the stomach. It activates both stimulatory 
and inhibitory controls of acid secretion and in these respects it simulates the 
response to eating. The reproducibility of the GRP test was assessed and was 
found to be high for both gastrin and acid secretion.
a
Î :i'fi
Using this new tool we studied acid secretion in a variety of subjects with 
and without H pylori infection. W e have found that GRP stimulated acid 
secretion is increased six fold in DU patients with the infection compared to H
pylori negative healthy volunteers (true normals). This exaggerated acid 
response is likely to represent a key pathophysiological defect which underlies II
DU disease. W e have demonstrated for the first time that eradication of H  
pylori infection leads to normalisation of basal and GRP stimulated acid 
secretion in DU patients. These novel findings have shed considerable light on
12
the understanding of the pathophysiology of DU disease and the role of H  
pylori infection in it.
W e have also shown for the first time that GRP stimulated acid secretion is 
increased two to three fold in H pylori positive healthy volunteers compared to 
true normals. This secretory abnormality also fully resolves following 
eradication of the infection. Since half the world's population is colonised with 
H pylori, it is essential that all future gastric secretory studies ensure that their 
control subjects are negative for the infection. The presence of the secretory 
abnormality in healthy volunteers may also be of relevance to other upper Gl 
diseases such as reflux disease.
W e proceeded to investigate the mechanism of the exaggerated acid 
response to GRP in DU patients and presented evidence compatible with this 
being due to impaired inhibitory control of acid secretion.
W e proceeded to examine the effect of the most commonly prescribed 
medication for dyspepsia, i.e. ranitidine, on acid secretion in healthy 
volunteers with and without H pylori infection. W e showed that a two month 
course of ranitidine leads to a doubling of basal acid output and a 68%  
increase in GRP stimulated acid output two days after withdrawing treatment. 
This rebound acid hypersecretion is not associated with any significant change
■f.
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in gastrin concentrations and fully resolves within ten days of stopping 
ranitidine. These findings may offer an explanation for the common clinical 
problem of rapid resurgence of dyspeptic symptoms following discontinuation 
of acid suppressive therapy.
Finally, we used the GRP test to study acid secretion in patients with non 
ulcer dyspepsia (NUD) and H pylori infection. W e showed that a significant 
proportion of NUD patients had an exaggerated acid response to GRP similar 
to DU patients i.e. they displayed the DU diathesis. This raises the exciting 
possibility that this group of NUD patients may also be cured by eradication of 
their H  pylori infection.
    .
CHAPTER ONE
A GENERAL INTRODUCTION 
ON HELICOBACTER PYLORI 
INFECTION
14
_     . . .
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1.1. HISTORICAL BACKGROUND
Spiral organisms in the human stomach have been described by Bottcher 
as far back as 1874 (1) and various workers identified spirochaetes in animal 
and human stomachs during the first half of this century. In 1975, Steer noted 
spiral bacteria closely apposed to the gastric mucus-secreting cells, but culture 
only yielded Pseudomonas aeroginosa (2). In 1979, Fung et al, working at the 
Royal Perth Hospital in Western Australia, published histological and 
ultrastructural studies of the gastric mucosa in which spiral bacteria were seen, 
but these were judged irrelevant because they did not invade the mucosa (3). 
Warren, the histopathologist working at the same hospital, did however 
correlate them with the presence of polymorphonuclear leukocytes (4).
In 1981, a young Gastroenterologist by the name of Barry Marshall, was 
asked to review with the help of Warren, the patients in whom large numbers 
of gastric spiral bacteria had been seen. One of these patients had been 
treated fortuitously with tetracycline and he reported resolution of his dyspeptic 
symptoms and subsequent endoscopic biopsy showed that the antral gastritis 
had also resolved (5). This finding prompted the subsequent work in which 
gastric biopsies from 100 consecutive patients were examined. Gastric 
biopsies were examined by culture, Gram staining and histology. Among the 
first 34 specimens, six were positive by Gram staining. Culture, however, did
r 's l
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not yield any growth because the incubation period was limited to 48 hours. 
Fortunately, however, the 35th specimen was left incubating for five days as 
this coincided with an Easter holiday. When the plates were finally examined, 
a pure growth of 1mm transparent colonies was seen. These proved to be H  
pylori and the date of this significant advance was April 14th, 1982 (1).
The bacteria were initially named Campylobacter pyloridis by Skirrow (6) 
but the rules of Latin grammar required the changing of the name to 
Campylobacter pylori. Subsequent studies indicated that the H  pylori had 
different taxonomic features from the genus Campylobacter and a new genus 
"Helicobactei"' was created to accommodate it. The name Helicobacter was 
proposed by Goodwin and was accepted in October, 1989 (1).
In the relatively short period since its discovery, H pylori has literally 
revolutionised our thinking about upper Gl Pathology. A massive amount of 
research has been conducted on all aspects of the infection and it has now 
been linked with gastritis, duodenal ulcer disease, gastric ulcer disease, non 
ulcer dyspepsia and gastric cancer. H pylori has become the most topical 
subject in Gastroenterology and arguably the most exciting breakthrough in 
Medicine in recent years. It promises to enhance our understanding not only of 
pathophysiologic mechanisms in upper Gl disease but, perhaps more
■I;
_       . .
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importantly, as a model of the effect of an infection on the elaborate neuro­
endocrine interactions in other organs.
with more than half the world’s population carrying the organism. The
uncommon in young children and low economic status predicts H  pylori 
infection. Immigration accounts for the isolated areas of high prevalence in 
some Western countries (7). The apparent increase in the prevalence of H  
pylori m ih  age lead some to believe that the infection is commonly acquired in 
adulthood and an incidence of 1-2% per annum has been estimated. However, 
more recent epidemiological data indicate that H  pylori epidemiology is 
compatible with a cohort effect in that cohorts born before 1940 have a far 
greater incidence of infection than subsequent ones (7).
Generally speaking, the prevalence of H pylori is much higher in 
developing countries compared to Western countries (8). Furthermore, the
I
1.2 EPIDEMIOLOGY OF H PYLORI INFECTION
1.2.1 Prevalence
H pylori is perhaps the commonest chronic bacterial infection world-wide
If
prevalence of H pylori in Western countries is approximately 20% in persons 
below the age of 40 and 50% of those above the age of 60 years. H pylori is
II
I
I;
I
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infection is acquired at a much earlier age so that by the time subjects reach 
early adulthood, the majority will have acquired the infection. The reason for 
the higher prevalence of H pylori in developing countries is thought to be a 
reflection of the poor living standards and hygiene which prevail over large 
sections of these populations. Transmission through the oral-oral and/or 
faecal-oral route facilitate the rapid spread of the infection under 
circumstances of overcrowding, lack of hot water supply, and poor hygiene (9).
1,2.2. Duration of Infection and Re-infection with H pylori
Once acquired, H pylori infection persists lifelong with a spontaneous 
eradication rate of <1% per year (10). Studies which examine re-infection 
following eradication of H pylori suggest that the recurrence is rare. During a 
total 314 patient years of follow-up, Borody et al, had only two cases of re­
infection following eradication treatment (11). When the recurrence occurs, it is 
usually diagnosed within six months of ending treatment. It is likely that cases 
of reinfection are probably recrudescence and not re-infection.
1.2.3 Source and Mode of Transmission
H pylori has never been cultured from the environment although it is able 
to survive for several days in distilled water, saline, and sea water if these are 
kept cool (12). Transmission is most probably by close contact between 
humans. The oral-oral and faecal-oral routes are thought to be involved in the
_________________
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transmission of H pylori between humans. H  pylori can be cultured from gastric 
juice (13). It has also been cultured from dental plaque of asymptomatic 
volunteers (14). It has recently become possible to culture H  pylori trom faeces 
(15).
1,3- DIAGNOSIS OF H PYLORI INFECTION
1.3.1. Histological Diagnosis
Warren demonstrated H pylori on gastric epithelium using the Warthin- 
Stary stain, a silver staining technique used for detection of spirochaetes in 
tissue section (4). Simplified histochemical stains have been introduced, the 
most widely employed being a modification of the Giemsa stain (16). There is 
little to choose between the many staining methods currently employed for 
detection of H pylori. W hat is more important, however, is a diligent, 
enthusiastic and well informed histopathologist.
1.3.2 Microbiological Tests
Helicobacters are microaerophilic bacteria and for their isolation in vitro, 
a microaerophilic atmosphere is required where the oxygen content is reduced 
to around 5%. These conditions are thought to reflect those found in the 
gastric mucosa. H  pylori colonies are not visible before 2-3 days of incubation 
and may take 7 or more days to appear. A  variety of methods have been used
20
to transport gastric biopsies, preserving H  pylori prior to culture. These include 
Stewart's transport medium, saline, 20% glucose solution and various broth 
media.
Culture of biopsies for H pylori is relatively expensive and is unnecessary 
unless antibiotic sensitivities are required. Culture to detect live bacteria and 
the new ultrasensitive PCR tests will assist in the interpretation of therapeutic 
trials and epidemiological studies.
I
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1.3,3, Urea Breath Tests
Kline and Graham wrote that "the principle of carbon breath tests is 
based on isotopic carbon tracers which exploit the concept of a target bond 
that links a low molecular weight, isotopically labelled group to the remainder 
of the substrate molecule. Cleavage of the target bond releases the labelled 
moiety that may be, or may undergo, subsequent conversion to carbon dioxide 
which is exhaled in the breath. The presence of the labelled carbon dioxide in 
breath signals the presence of an enzyme which acts on the target form, and 
the rate and extent of isotopic CO2  production can be used to estimate the
quantity of enzyme present" (17).
In the case of H pylori, the enzyme is a urease which is capable of 
splitting urea into CO2  and ammonia. The urea can be labelled with either ^^C
I
:
■k:
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or Once the labelled urea is ingested, it is rapidly hydrolysed in the
presence of H pylori urease to 13 /1 4 0 0 2  and ammonia. The labelled CO2  is
then absorbed and excreted in the exhaled breath which would be collected 
and analysed. If H pylori is not present, hydrolysis does not occur and labelled 
CO2  is not produced. Serial sample collection and analysis permit the
construction of excretion curves. The 13o is a natural non-radioactive isotope
and can be measured relative to 12c by gas isotope ratio mass spectroscopy.
In recent years, mass spectrometers specifically designed for I^ C  gas
analysis have been developed. I^C , the radioactive isotope of carbon, is 
measured by liquid scintillation counting.
Urea breath tests have certain advantages over other methods of 
diagnosing H pylori. Unlike serology, urea breath tests reflect current infection 
status and become negative immediately after suppression or eradication of H  
pylori. Breath tests have an advantage over endoscopic biopsy in sampling a 
much larger surface area of the stomach with less risk of a sampling error. The
13c urea breath test does not involve any radiation risk but requires an
expensive mass spectrometer for analysis. The 1^0 urea breath test is 
relatively inexpensive but involves the administration of a small dose of 
radioactivity which has been equated to the dose received from a standard
I
Ï
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I 
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chest x-ray. The urea breath tests are regarded by many as the most useful 
means of assessing H  py/or/status.
1.3,4. Serological Tests
Serology provides the easiest and most convenient approach for the 
diagnosis of H  pylori infection. A number of serological methods have been 
developed, but the enzyme-linked immunosorbent assay (ELISA) has the 
advantage of simplicity, reliability and cost. Generally, such tests have 
sensitivities and specificities of >90% and the recent identification of 
appropriate antigens has lead to significant improvements in these test criteria.
Serology is of great value in epidemiological studies and has played an 
important role in defining the association between H pylori infection and a 
variety of gastroduodenal diseases, especially gastric cancer. Serology may 
also be of great value in pre-screening of selected groups with dyspeptic 
symptoms who will benefit from eradication therapy and will reduce the 
endoscopic workload. The major disadvantage of serology is the slow fall in 
titre which occurs following eradication therapy. It is, therefore, not ideal for
considered only with caution.
assessing patients who have received eradication therapy. In addition,
il
treatment of seropositive patients, without prior endoscopy, should be
.1
ikI
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1-4, TREATMENT OF HELICOBACTER PYLORI 
INFECTION
Helicobacter pylori is a common bacterial infection world-wide. In spite of 
the availability of a large number of subjects for therapeutic trials and the 
extensive interest both from the scientific and pharmaceutical communities, 
eradication remains difficult. The difficulty in eradicating H pylori stems from 
the nature of this organism, its ecological environment and the host response 
to it. Unlike the majority of infectious agents, once H pylori has successfully 
colonised the stomach it persists, and unless an antibiotic regimen is able to 
completely eradicate it, cessation of therapy is followed by rapid 
recrudescence of the infection to pre-treatment levels within one month. An 
antibiotic regimen therefore has to abolish all bacteria present and not simply 
reduce the bacterial load to allow the host factors to eliminate the pathogen.
H pylori resides differentially within the stomach on the surface of the 
epithelial cells and beneath the mucus layer. This position is protected from 
gastric acid by the underlying secretion of alkali. The mucus layer also acts to 
interfere with the diffusion of antibiotics. The low intragastric pH also 
inactivates many antibiotics rendering them ineffective against H pylori. In 
addition, the constant emptying of the stomach reduces the effective antibiotic 
concentration necessary to act on the bacteria.
.........................
The ability of H  pylori to cope with an acid environment has largely lead
possession of the urease enzyme therefore enables H pylori to colonise an 
inhospitable environment and gives it an advantage over other organisms 
which have not developed this ability to cope with acid.
to be effective against H pylori in vivo. The observation that treatment of 
duodenal ulcer with this drug led to a reduced recurrence rate compared with 
other compounds lead indirectly to the discovery that H pylori eradication
24 I
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to its success as a parasite. Its powerful urease enzyme splits urea present in
■fthe gastric juice to ammonium hydroxide, an alkaline solution, which then 
surrounds the organism while it is present in the lumen of the stomach. 
Subsequent to that, the organism is able to penetrate the submucous layer 
which overlies the gastric epithelial cells where the pH is close to neutral. The ::
'
Colloidal bismuth subcitrate was the first antimicrobial compound found
prevented ulcer relapse. Used alone, bismuth compounds are only successful
■ B
in 10-30% of individuals. Combination with other antibiotics led to higher i
eradication rates and the concept of triple therapy evolved. Triple therapy has 
become the treatment of choice in recent years (18). Most regimens use 
colloidal bismuth subcitrate together with metronidazole and tetracycline or 
amoxycillin. The doses and duration of treatment with these three drugs are 
widely variable and there is no standard regimen which has been found to be
superior to the others. In our own Unit in Glasgow we have had a 90%
'I
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eradication rate with triple therapy consisting of De-Nol 120mg t.i.d., 
metronidazole 400mg t.i.d. and amoxycillin SOOmg t.i.d. The three drugs are 
given for a total of three weeks. In patients who are allergic to penicillin, 
tetracycline at a dose of 250mg t.i.d. is given instead.
In recent years a new approach to the eradication of H pylori emerged 
with the use of an acid inhibitor plus one or two antibiotics. The commonest 
prescribed regimen combines omeprazole at a dose of 20mg b.d. with 
amoxycillin SOOmg ti.d . Eradication rates of between 30-80%  have been 
reported. An eradication rate of 78% was reported with omeprazole 20mg b.d. 
and clarithromycin SOOmg t.i.d. (19). The majority of patients will respond to 
either triple therapy or omeprazole in high dose plus an antibiotic. In patients 
who have a metronidazole resistant organism, it is logical to start with the 
omeprazole/amoxycillin or clarithromycin combination. If a patient fails to 
respond to either regimen it is advisable to try the other if indication is still 
present. It is important, however, to emphasise the importance of compliance 
and the risk of inadequate treatment with the emergence of resistant strains. 
Most patients tolerate triple therapy and other regimens reasonably well with 
only minor side-effects, the commonest of which being diarrhoea, nausea and 
occasional dyspepsia. Serious complications such as pseudomembranous 
colitis are exceedingly rare.
   _  .........................
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1.5.1. Chronic Gastritis
gastritis and dyspeptic symptoms. H pylori colonisation of the gastric mucosa 
was demonstrated in those cases (20,21); (5) experimental studies in animals; 
(6) the resolution of the histological changes of gastritis including reduction in 
the inflammatory activity in the gastric mucosa and healing of the
3
1.5. DISORDERS ASSOCIATED WITH H PYLORI 
INFECTION II
' I
Helicobacter pylori is now well established as the cause of Type B antral 
gastritis. This causal relationship is supported by a number of facts which 
include:- (1) a strong association of chronic gastritis with H pylori infection in 
60-90%  of patients; (2) the absence of H  pylori in the autoimmune forms of 
chronic gastritis and in normal gastric mucosa; (3) the possession of H pylori 
of a number of virulence factors capable of initiating gastritis; (4) the fulfilment
of Koch's postulate in that volunteers who ingested H  pylori later developed
■
morphological lesions following suppression and/or eradication of the infection
by antibiotics.
H pylori associated chronic gastritis is thought to start from the antral 
region of the stomach and progressively spread to the mucosa of the gastric 
body. Chronic gastritis induced by the infection is characterised by a neutrophil 
granulocyte infiltrate, which is detected within the epithelium and the lamina
!
:'-S
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propria. While H pylori is detectable in the active form of chronic gastritis, it 
disappears in the inactive form which is considered to be a later stage in the 
evolution of H  pylori gastritis. Progression of chronic gastritis is accompanied 
by varying degrees of atrophy (22). H pylori infection induces a characteristic 
histological appearance and for this reason a new system of classifying 
chronic gastritis relying on aetiology, topography and morphology has been 
suggested ( the Sydney System) (23).
1.5.2. Gastric Ulcer
The association between H pylori and gastric ulcer is less frequent than 
between H pylori and DU and is approximately 60-70%. This is largely due to 
the fact that a large proportion of gastric ulcers are caused by non-steroidal 
anti-inflammatory drugs. Sidebotham and Barron, 1990, proposed that H pylori 
infection predisposes to gastric ulceration through alteration of the mucus 
glycoprotein composition with influence on bicarbonate entrapment, allowing 
excessive backdiffusion of hydrogen ions (H+) with breakdown of the mucosal 
barrier (24). The dense intra-epithelial infiltration of neutrophils, probably 
followed by an increase in free oxygen radicals, may be another element in the 
pathogenesis of gastric ulcer.
'i
i l
I
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1,5.3 Gastric Cancer
According to the Lauren classification, gastric adenocarcinoma can be
association has been sought between the infection and the intestinal type of 
gastric cancer.
.subdivided into the intestinal ( the most prevalent ) and the diffuse forms. The 
intestinal form typically arises in the antral region of the stomach. Due to the 
well established role of H pylori infection in chronic antral gastritis, an
Ï
.1m
ii"In support of this association is the finding that H pylori induced antral 
gastritis progresses to atrophy after 10-20 years (25). Intestinal metaplasia, 
which is considered to be a precancerous condition follows 10-20 years after 
the appearance of atrophic changes (26,27). A  precancer-cancer sequence 
has therefore been hypothesised which suggests that H pylori induced chronic 
superficial gastritis evolves through chronic gastritis with progressive atrophy 
to intestinal metaplasia, dysplasia and gastric cancer. This sequence of 
histological changes requires the acquisition of H pylori infection in early 
childhood.
;
Epidemiological studies have shown that there is a geographic association
ibetween those areas of the world with high rates of gastric cancer and those
" î ' i iwith a high prevalence of H  pylori infection (28,29), although there are
f:
important exceptions to this general pattern, most notably in Africa (30). The
„-3„
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most convincing epidemiological evidence in support of an association is that 
from three prospective studies (31-33). In these studies blood was taken from 
healthy subjects and stored, and H pylori antibody status was later assessed in 
those who went on to develop gastric cancer. In all three studies, infection was 
significantly more common in the gastric cancer patients than in appropriately 
matched control groups.
1.5.4. Non Ulcer Dyspepsia (NUD)
The prevalence of H pylori infection in patients with NUD is higher than in 
normal age-matched controls. The reported prevalence varies from 50-87%  
depending on the series. Due to the controversial definition of NUD and the 
complexity of symptoms, the association with H pylori has been difficult to 
define. In particular it is difficult to define a particular symptom complex which 
could be linked to the infection although a higher symptom score has been Ireported by Lambert et al (34). Rathbone et al showed that belching is more
It'
:'"3
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frequent in H  pylori positive patients (35), and Rokkas et al demonstrated a 
positive relationship between H pylori infection and postprandial bloating (36).
-
Studies which examined the effect of eradicating H pylori infection on 
symptoms in NUD patients also yielded conflicting results but the consensus 
seems to be that eradication therapy improves symptoms in a subpopulation of 
patients.
3
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The major challenge in this field is to define this subpopulation of patients 
whose symptoms are caused by the infection and who are therefore likely to 
benefit from its eradication. This area is of relevance to the work presented in 
this thesis and will be discussed in greater detail later.
1.5.5. Duodenal Ulcer Disease
The highest prevalence of H  pylori infection is found in duodenal ulcer 
patients. It is now generally accepted that more than 95% of DU patients have 
the infection. In all these patients the presence of the infection is associated 
with the presence of chronic gastritis which profusely involves the antral 
mucosa, often with mucosal lymphoid follicles. The body type mucosa is 
normal or only mildly inflamed and does not show any atrophy of acid 
secreting glands. This is the diffuse antral pattern of gastritis described by 
Correa, which is now known to be very closely associated with H pylori 
colonisation. The proportion of H pylori positive patients who have this pattern 
of gastritis varies and is thought to be in the region of 35%.
The importance of the role of H pylori in the aetiology of duodenal ulcer 
is most convincingly demonstrated by the absence of ulcer relapse in patients 
in whom H  pylori has been eradicated, an effect which is independent of any 
mucosal protective effect of bismuth compounds. A number of important
A " _. . 3 A l i : ' A l . : ___________________________________________________________________       . _____ ______  _______  ______
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studies have now shown that eradication of H  pylori infection is associated 
with a dramatic lowering of the ulcer relapse rate (37-40) adding strong 
support to the causal relationship between H pylori infection and DU disease. 
This association is now so well established that a group of scientists who met 
at the NIH in Bethesda, USA, have recently issued a consensus statement in 
which they recommend that all patients with DU or GU disease who have H  
pylori infection should now be treated with eradication therapy regardless of 
whether they are suffering from the initial presentation of the disease or a 
relapse (41).
There are two main schools of thought regarding the role of H pylori in 
the pathogenesis of duodenal ulcer disease. The first argues that H pylori 
causes duodenal ulcers through a direct effect on the patches of gastric 
metaplasia which are frequently found in the duodenal mucosa of patients with 
duodenal ulcer. Duodenal ulcer patients are known to be hypersecretors of 
acid and this leads to the development of gastric metaplasia in the duodenum 
either as a direct result of epithelial damage caused by the acid/peptic attack 
or as a result of the inflammation secondary to this damage. These patches of 
gastric metaplasia are later colonised by H pylori organisms gaining access 
from the antral region. The presence of H pylori in these metaplastic patches 
leads to further inflammation and further metaplasia with a vicious cycle 
developing in which continued acid/peptic activity together with inflammation
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act to overwhelm the normal protective mechanisms in the form of mucus- 
bicarbonate secretion and rapid cell replication and repair. W hen any of these 
repair mechanisms are overwhelmed by these or superimposed factors, such 
as NSAIDs or smoking, the balance will ultimately be tipped towards ulcer 
formation. However, against this hypothesis is the finding that prepyloric ulcers 
are found with equal frequency in patients with and without H pylori infection, 
suggesting that the presence of the infection is not necessary for the 
development of the actual ulcer.
The second school of thought argues that H pylori infection predisposes 
to duodenal ulceration through its disturbance of gastric physiological 
processes. Since this subject is of major relevance to the work presented in 
this thesis, it will be discussed in more detail in chapter 3 of the thesis.
In the next chapter a more detailed account of DU disease is given to set 
the background to the majority of work undertaken in this thesis.
_ __   _    „     . . . .  ..     .........
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CHAPTER TW O
DUODENAL ULCER DISEASE
____ j
2.1. INTRODUCTION
Peptic ulcers were once so common in industrialised nations that they were 
virtually considered stigmata of civilisation. Despite the huge volume of 
literature dealing with the different aspects of peptic ulcer disease, the exact 
pathogenesis of this condition remained largely unknown. The discovery and 
successful culture of H pylori in the early 80's has revolutionised our thinking 
about peptic ulcer disease.
Peptic ulcers are chronic, most often solitary lesions that occur in any 
level of the gastrointestinal tract. Approximately 98-99% of peptic ulcers occur 
in either the duodenum or the stomach in a ratio of about 4:1. About 10-20% of 
patients with gastric ulcers have a concurrent duodenal lesion. Wherever they 
occur, chronic peptic ulcers have a fairly standard, virtually diagnostic gross 
and microscopic appearance. Despite this uniform morphology, gastric and 
duodenal ulcers may represent two somewhat distinctive diseases. Different 
influences are thought to be involved in their pathogenesis and there are 
further contrasts in their genetic linkages. The work presented in this thesis is 
largely concerned with the pathogenesis of duodenal ulcer disease and for this 
reason all subsequent discussions will be limited to DU disease.
_______________________   . . .   . 3
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2.2 EPIDEMIOLOGY OF DUODENAL ULCER DISEASE
2.2.1. Prevalence and Incidence
Prevalence: A  number of well designed and conducted studies and 
surveys show that in developed countries approximately 10% of the population 
are likely to be affected by peptic ulcer during their lifetime, with the point 
prevalence for active ulcer disease about 1% (42).
Incidence: Several studies performed over three decades point to a 
yearly incidence of peptic ulcer of between fifteen and thirty cases per one 
thousand.
2.2.2. Trends in Ulcer Occurrence
Peptic ulcer disease was infrequently recognised before the beginning of 
the 20th century. The occurrence of DU disease then increased steadily until 
1960. Over the last 20 years, however, a number of indirect indicators such as 
rates of hospitalisation, operation, and death suggested a marked decrease in 
DU and possibly in GU in England, Europe and the United States (42). The 
apparent decline in the number of hospitalisations for uncomplicated ulcer 
contrasts with trends regarding ulcer complications. Rates of hospitalisation for 
ulcer haemorrhage fell only slightly for DU while perforations were unchanged.
Ï :
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Death rates for ulcer disease complications appeared to decline for men but 
remained stable or possibly increased for women (42).
In the past, DU disease was commoner in males than in females. For 
example, the male to female ratios for DU hospitalisation and mortality rate 
were respectively 1.8:1 and 2.4:1 in 1970. Both ratios decreased in 1983 to 
1.3:1 (43). The trends in ulcer occurrence reflect declining rates, particularly 
for younger men, and increasing rates, particularly for older women. Age- 
cohort phenomena account for these changes with at least three age and 
gender dependent environmental elements. The first is the fact that prevalence 
of H pylori infection increases with age. This apparent increase as mentioned 
previously reflects an age-cohort phenomenon. Improved hygiene and 
sanitation in developed countries predicts decreased exposure at young age 
and probably a decreased incremental infection rate as people age. The 
second element is the fact that complications from NSAID ulcers increase as a 
function of age, in parallel with an increased rate of prescription. The third 
element relates to smoking which is declining in younger people, particularly 
male, and is increasing in women, possibly affecting the declining male to 
female ratio.
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2.2.3. Regional and Societal Variables
It is widely believed that DU affects highly stressed professionals and 
executives. However, the available evidence suggests that DU is slightly more 
common among unskilled labourers (44). There is an inverse relationship 
between peptic ulcer and family income (45), matched by a similar relationship 
between H pylori infection and family income.
There is some variation in the prevalence of peptic ulcer disease between 
geographic regions. For example, the prevalence of DU is higher in Scotland 
and Northern England compared to Southern England (44). Several factors 
may account for this regional variation including diet and the regional 
distribution of H  pylori infection. It is interesting to note that in the Aboriginal 
population of Australia, peptic ulcer disease is virtually unknown in parallel 
with a very low prevalence of H pylori (46). In contrast, some areas of Ethiopia 
have a very high prevalence of H pylori seropositivity matched by a high | |  
prevalence of DU disease (47). On the other hand, populations in Northern 
Nigeria have a high serology prevalence of H pylori with a low prevalence of 
ulcer disease (48). This suggests that other variables are clearly involved in 
the pathogenesis of duodenal ulcer disease.
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2.2.4. Diseases Associated With Duodenal Ulcer Disease
Reflux Oesophagitis and Barrett's oesophagus
DU disease is commonly associated with reflux oesophagitis and the link 
is thought to involve acid hypersecretion. Because of the association of DU 
and oesophagitis, an association may also exist with Barrett's oesophagus and 
oesophageal adenocarcinoma.
Chronic Pulmonary Diseases
There is an association between peptic ulcer disease and chronic 
obstructive airways disease. Up to 30% of patients with chronic lung disease 
have peptic ulcers and the frequency of chronic lung disease in peptic ulcer 
patients is increased 2-3 fold (42). Gastric ulcers appear to be more closely 
associated with lung disease than DU but both are associated. The major 
factor underlying this association is thought to be smoking which affects both 
diseases.
Evidence is available for the association of peptic ulcer disease and 
alpha-1-anti trypsin deficiency and cystic fibrosis. The relative risk for peptic 
ulcer and alpha-1-antitrypsin deficiency is estimated to be 1.5:3 times greater 
than the general population (49). In a study by McColley et al, sixty cystic 
fibrosis patients were studied (50). Forty of these were white and twenty were
' Ï
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black and 13% of the black patients but none of the white patients developed 
peptic ulcer disease. It is unclear whether the difference between the two 
groups could be accounted for by the higher incidence of H  pylori in the black 
patients. The low incidence of DU in cystic fibrosis in the white patients, 
however, suggests that decreased pancreatic bicarbonate secretion per se is 
not a major risk factor for ulcer disease.
Cirrhosis
The incidence and prevalence of DU appears to be increased in cirrhotic 
patients. A  study by Rabinovitz et al examined endoscopically 216 males being 
evaluated for liver transplantation (51). They found an apparently increased 
prevalence of active duodenal ulceration in cirrhosis caused by alcoholism 
(12.2%), chronic active hepatitis due to HBV (9.4%), and primary sclerosing 
cholangitis (8.5%).
The mechanism underlying the association between peptic ulcer disease 
and cirrhosis is unclear. There is conflicting data regarding serum gastrin 
levels and acid secretion in cirrhotic patients (52,53). Decreased hepatic 
metabolism of Gl hormones and altered mucosal blood flow have been 
hypothesised as pathogenic factors. There are no reports on the prevalence of 
H pylori infection in cirrhotic patients. In addition, there has been no studies 
examining the subset of patients who develop ulcers, particularly in relation to
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acid secretion. It is known that portacaval shunting increases the sensitivity to 
endogenous and exogenous gastrin but it is not clear how this increased 
sensitivity can lead to an ulcer diathesis (53).
Renal Failure and Transplantation
There are conflicting data regarding the prevalence of peptic ulcer during 
maintenance haemodialysis. Some studies suggest that the prevalence of DU 
is increased in patients prior to the commencement of haemodialysis. There is 
an increased risk of DU after renal transplantation. Acid secretion may be low, 
normal, or high in chronic renal failure on haemodialysis. During 
haemodialysis, basal acid hypersecretion has been increased in some series 
but not in others (42). increases in acid secretion following transplantation 
have been reported but are controversial. Although hypergastrinaemia occurs 
in renal failure, an inverse relationship to acid secretion reflects underlying 
atrophic gastritis with no evidence for gastrin driven acid hypersecretion. 
There is no solid support for decreased renal metabolism of gastrin resulting in 
hypersecretion (42).
In renal transplantations, it appears that many ulcer cases are a form of 
stress ulceration. Peptic ulcer in uraemic patients is not linked to H pylori as 
the occurrence of antibodies with H  pylori is similar in renal failure patients with 
or without peptic ulcer (54).
A:-. 3; ■ ;■  '         ... .   __.......... .............................................................
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Other Disease Associations
Peptic ulcer disease is more common in patients admitted with venous 
thromboembolism, pulmonary embolism, coronary artery disease, patients with 
reduced exocrine pancreatic function, patients with renal calculi associated 
with multiple endocrine neoplasia (MEN I) syndrome, reflecting the presence of 
both gastrinoma and hypoparathyroidism (42).
2.2.5. Disorders Associated With A Decreased 
Incidence Of Duodenal Ulcer Disease
Patients with atrophic body gastritis ( type A gastritis) have a decreased 
incidence of peptic ulcer. Auto-immune diseases associated with atrophic 
gastritis such as Addison's disease, auto-immune thyroid disease and 
hypoparathyroidism also have a low incidence of peptic ulcer (55).
There Is also a negative association between gastric carcinoma and DU 
disease. This is probably due to the fact that most patients with gastric 
carcinoma have advanced atrophic gastritis with acid hyposecretion which 
reduces the risk of DU disease.
I
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2.3. AETIOLOGY OF DUODENAL ULCER DISEASE .I
The pathogenesis of duodenal ulcer disease is multi-factorial. Common 
and uncommon causes are implicated. By far, the commonest forms of 
duodenal ulcer are associated with H  pylori infection, non-steroidal anti­
inflammatory drug usage and stress ulceration. Amongst the uncommon 
specific forms of DU disease are: gastrinoma, mastocytosis, basophilic 
leukaemias and antral G cell hyperfunction/hyperplasia. Other infections, in 
particular viral, such as herpes simplex virus Type I and CMV, have also been 
implicated. Vascular insufficiency caused by crack cocaine-associated 
perforations has been described. Radiation induced and chemotherapy 
induced duodenal ulcers are also reported in the literature.
Acid hypersecretion sets the stage for many cases of duodenal ulcers but it 
is naive to think that ulcers occur simply from the primary failure of regulatory 
mechanisms of acid secretion or mucosal defence. It is more likely that ulcers 
occur when the normal mechanisms controlling acid secretion and mucosal 
defence are disrupted by super-imposed factors such as H pylori infection, 
NSAID usage etc. Although NSAID induced and stress induced ulcers are 
common, they will not be specifically discussed in the subsequent sections as 
they are not directly related to the work presented in this thesis. The following 
sections review some of the abnormalities which have been documented in
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duodenal ulcer disease and their relevance to the pathogenesis of duodenal 
ulcer disease is discussed.
2.3.1 ■ Genetics Of DU Disease
Familial Aggregation of DU
Twenty-50% of DU patients have a positive family history for DU compared 
with 5-15% of non-ulcer subjects (49). First degree relatives of patients with 
DU have a three-fold increase in the prevalence of DU but not of GU. 
Concordance of DU is more common in monozygotic than dizygotic twins, 
suggesting a genetic element but incomplete concordance of ulcer in 
monozygotic twins indicated that noh-genetic factors were also operative
(49.56).
Genetic Markers in Peptic Ulcer
Several indirect genetic markers have been linked to peptic ulcer disease. 
Subjects with blood group O have a 30% increase in risk of DU compared to 
subjects with blood groups A, B or AB. There is a 50% increase in the risk of 
DU in subjects who do not secrete ABO blood group antigens into body fluids 
(the so-called non-secretors), such as saliva. Subjects with both blood group O 
and non-secretor status have a 150% increase in risk of developing DU
(49.56). It is not clear how H pylori infection fits with these old associations. A
■
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report by Mentis et al indicated that ABO status was related to ulcer 
independently of H pylori (57).
Familial Clustering of DU Disease
There have been reports suggesting that association between peptic ulcer 
disease and autosomal dominant inheritance of hyperpepsinogenaemia I, 
However, Mertz et al re-analysed sera from these cases and discovered that 
there was an 87% seropositivity for H pylori infection in subjects with a 
pepsinogen I level >100ng/ml. The seropositivity was only 35% in those with 
pepsinogen I level less than this value (58). Both pepsinogen I and antibodies 
to H pylori increased with age of the subjects in a fashion very similar to that 
observed in other studies of H  pylori antibodies. It is likely therefore that the 
prevalence of peptic ulcer disease and hyperpepsinogenaemia I reflects 
familial clustering of H pylori infection rather than autosomal dominant 
inheritance of hyperpepsinogenaemia I.
Similarly, old data suggested that a subset of DU patients who are 
hypergastrinaemic have hyperfunction of their antral G cell population. 
However, since the discovery of H  pylori and its resultant hypergastrinaemia, it 
is more likely that the association between hypergastrinaemia and peptic ulcer 
disease is caused by H pylori.
   _     . . . . . . . . .  . . .  . .
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2.3.2. Psychologic Factors In Peptic Ulcer Disease
Psychodynamic factors have always been implicated in the pathogenesis of 
peptic ulcer disease. These factors have not been correlated with 
pathophysiologic parameters against the background of H pylori to define the 
subset of persons in whom these mechanisms constitute important, 
predisposing or exacerbating factors.
Psychologic Conflict and Personality Type 
This subject is surrounded by controversy and few conclusions can be made 
from the published work. The classic theory defined the ulcer personality 
characterised by an exaggerated dependency /  independency conflict. This 
view is now largely rejected by most investigators. It appears that duodenal 
ulcer patients frequently display personality disorders suggesting a 
psychodynamic element in the pathogenesis of their disease. The nature of the 
personality disorders is variable, reflecting the heterogeneity of the population 
examined as well as the methodology and definitions used by the 
investigators.
Role of Physical and Psychologic Stress
There is no doubt that peptic ulcer disease seems to be exacerbated by 
stressful life events. During the blitz of London in the autumn of 1941, an 
increased number of perforated peptic ulcers were reported (59). Twenty-five
-A = - V .. ■ ■: ■'■•...■■■•A
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per cent of prisoners of war developed DU during a follow-up period compared 
with an 11% occurrence in non-captured veterans (59). The person's 
interpretation and reaction to stress is probably more important than the 
intensity of external stress. It is important to distinguish between acute 
stressors, which are not excessive in DU patients, and chronic stressors such 
as high goal frustration, etc., which have been associated with the onset and 
relapse of ulcers (60).
The mechanism potentially linking psychologic factors to ulcers remain 
speculative. It is important to stress that DU occur only in patients with an 
adequate parietal cell mass to support an acid/peptic process. It is tempting to 
speculate that psychologic factors, via vagal mechanisms, may underlie an 
increase in basal and nocturnal acid outputs observed in some ulcer patients. 
Again it remains speculative whether chronic psychologic stress alters parietal 
cell mass. It is known that chronic vagal stimulation increases acid secretory 
mass in an animal model (61).
Psychodynamic factors may also alter mucus secretion, mucosal blood 
flow, and gastric motility and produce mucosal damage not clearly explained 
by an increase in acid secretion. Neural factors may play a role in the immune 
response and susceptibility to viral infection (62), providing a precedent for
I
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psychodynamic factors possibly influencing gastric inflammatory response and 
resistance to H pylori.
I
f lI
48
2.3,3, Potential Risk Factors For DU Disease
A  number of potential risk factors for DU disease have been implicated 
over the years. In the section below three of these factors are discussed and 
their contribution to DU disease is evaluated.
(A) Cigarette Smoking
There is sufficient evidence to link smoking to peptic ulcer disease:
(1) Epidemiological studies indicate that smoking increases the risk for both 
DU and GU. This risk appears to be proportional to the amount smoked 
(63,64). However, in the light of the discovery of H pylori, the contribution of 
smoking to the pathogenesis of DU disease has been somewhat undermined.
(2) Smoking impairs ulcer healing and promotes recurrences. (3) Smoking 
increases the risk of complications and the need for surgery (65). (4) Death 
rates from ulcer disease are greater in smokers.
Several mechanisms have been proposed for the effects of smoking on 
ulcer disease. These include: increased gastric emptying promoting duodenal 
acidification, increased basal and maximal acid secretion, decreased 
pancreatic bicarbonate secretion, altered gastroduodenal motility leading to 
reflux of duodenal contents, increased pepsinogen I secretion, decreased 
gastric mucosal prostaglandin production and altered blood flow (64,66-69). In 
general, these several effects of smoking are modest, variable, and
    _ _
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controversial; no single factor adequately explains the clinical impact of 
smoking on ulcer disease and there is not yet consensus on which factors 
contribute to pathogenesis.
(B) Alcohol
High ethanol concentrations damage the gastric mucosal barrier to 
hydrogen ion resulting in acute gastric erosions and haemorrhages (70). The 
acute effects do not appear to cause either gastritis or chronic peptic ulcer.
The effect of alcohol on gastric acid secretion is controversial and appears 
to reflect a biphasic dose response: concentrations between 1 and 4%  
produced stimulation of acid secretion while higher concentrations had no 
effect or inhibited secretion (71).
W ine and beer are strong stimuli of acid secretion in humans, producing 
50-90% of maximal acid output. This stimulation of acid appears to be 
mediated to a large extent by gastrin (71,72).
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(G) Diet
It is widely believed among lay people that dietary indiscretion is a cause 
of ulcers. While certain foods, beverages and spices cause dyspepsia, there 
are no convincing data that such foods cause, perpetuate or reactivate peptic 
ulcers.
Coffee is a strong stimulant of acid secretion and produces dyspepsia in 
many subjects. This is most probably due to enhanced oesophageal reflux 
(73). Caffeine does not seem to be the culprit as decaffeination does not 
reduce either effects of coffee (73). It is interesting to note that subjects with 
NUD, but not DU patients, experienced more dyspepsia with coffee than did 
normal controls (74). Attempts to link coffee consumption as a risk factor for 
ulcer disease have failed.
A  variety of other caffeine- and noncaffeine- containing drinks (Coca-Cola, 
7 UP, and tea) also potently stimulate acid secretion, producing more than 
50% of maximal secretory response to pentagastrin (75).
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2,3.4, Abnormalities of Acid and Pepsin Secretion in DU 
Patients
Since the time of Schwartz with his famous dictum "No Acid : No Ulcer”, 
DU disease has been regarded as an acid/peptic disease. The arrival of H  
pylori infection on the scene has lead some to challenge this accepted wisdom 
and to propose a new dictum ” No H pylori ; No Ulcer”. However, a number of 
well established abnormalities of acid and pepsin secretion are present in DU 
patients and it is important to try and account for these in the light of our new 
knowledge of H pylori infection.
Maximal Acid Output
The maximal acid secretory response of the stomach is an indirect 
measure of the parietal cell mass. DU patients have an increased maximal 
secretory response to stimulation with pentagastrin, gastrin, histamine, 
betazole and caffeine compared to normal subjects (76-80). It has been 
estimated that DU patients on average have a 1.5-2 times greater parietal cell 
mass than control subjects (78,81,82). It is important to note that a great 
degree of overlap exists between DU patients and healthy controls with only 
20-50%  of DU patients having elevated maximal acid outputs.
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Basal. Nocturnal and Meal-Stimulated Acid Output
Basal acid output is increased in approximately one third of DU patients 
(76,79,83), Nocturnal acid output discriminates more effectively between DU 
patients and normal subjects (84-86) and is significantly higher in DU patients 
with little overlap with healthy controls. It is controversial whether meal-
stimulated gastric acid secretion is increased in DU patients. The results are
undermined by the difficulty of measuring acid output in the presence of food 
in the stomach. The acid secretory response to a meal appears to be
prolonged in DU patients, remaining elevated compared to normals in the
period 3 to 5 hours after a meal (79,83). Sustained acidification following a 
meal was also shown in studies which used continues pH monitoring (87-88).
Possible Mechanisms for the Increased Secretory Capacity and Drive in DU 
Patients
The increased parietal cell mass characteristic of some DU patients may 
be the result of genetic factors or environmental factors or both. It is possible 
that some individuals are born with a larger parietal cell mass which is then 
subject to a variety of factors, some of which may be environmental, which act 
to attenuate this cell mass. However, the trophic factors which maintain the 
oxyntic mucosal mass in normal subjects or promote an increased secretory 
mass in some DU patients remain unknown. Gastrin is implicated as an 
important trophic factor for oxyntic mucosa stimulating oxyntic mucosal growth
  ________   __........
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(89,90) and increasing secretory mass in gastrinoma patients. However, as will 
be discussed in chapter 3, H pylori infection causes increased basal, meal- 
and bombesin- stimulated gastrin release in subjects with H  pylori infection 
regardless of whether they are ulcer subjects or not. This finding renders 
studies of acid secretion and parietal cell mass in peptic ulcer uninterpretable 
unless H  pylori status is simultaneously considered in both ulcer subjects and 
normal controls.
The vagal nerve also exerts trophic control over the oxyntic mucosa (91). 
Thirlby and Feldman (61), using a dog model, showed that vagal stimulation 
from sham feeding repeated over a six week period increased acid output from 
vagally innervated, but not denervated, gastric pouch. Histamine has not been 
reported to exert trophic effects on the oxyntic mucosa.
Thus, gastrin or vagal mechanisms or both are likely to be involved in the 
apparent increased secretory capacity of DU patients.
Regarding the increased secretory drive seen in DU patients, it is likely 
that a complex process involving increased stimulatory or diminished inhibitory 
activity of the endocrine, neural, paracrine or autocrine regulatory pathways 
might result in increased basal and interdigestive secretory drives. The nature
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of these mechanisms and the abnormalities that result due to colonisation of 
the gastric mucosa by H pylori infection remain to be explored.
Pepsinogen and Pepsin
The human stomach produces two immunochemically distinct types of 
pepsinogen: pepsinogen I produced in the chief cells and mucus neck cells of 
the oxyntic mucosa and pepsinogen II which is present in the gastric body and 
antrum. Together they account for the acid protease activity of gastric juice.
Peptic activity is closely linked to gastric pH, with H^ ions converting 
pepsinogen to the active protease pepsin. The pepsin is inactivated when the 
pH of gastric juice rises above 4.0. Acid plus pepsin is much more ulcerogenic 
than acid alone (92), a fact which is reflected in the label “peptic” which 
describes the majority of ulcers.
Serum pepsinogen I concentrations are elevated in 30-50%  of DU patients. 
A  high serum pepsinogen I level increases the risk of developing DU (92). 
Hyperpepsinogenaemia I may be a predictor of refractory or recurrent ulcer. A  
high pepsinogen II level increases the risk for GU (93).
It has recently been found that pepsinogen I and II levels are increased in 
the presence of H  pylori infection (94), and eradication of the infection appears
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to reduce serum pepsinogen I (95). W hat is also interesting is the finding that 
the apparent familial association of hyperpepsinogen I with peptic ulcer 
disease reflects familial clustering of H pylori infection (58). It is likely therefore 
that the abnormalities in the pepsins described in association with peptic ulcer 
disease may be induced by H pylori infection. To date, no studies have 
attempted to test the hypothesis that elevated pepsinogen I levels mark the 
subgroup of H pylori positive subjects with an ulcer diathesis compared with H  
pylori positive subjects without ulcers.
The work undertaken in this thesis has sought to explore some of the 
mechanisms involved in the pathogenesis of DU disease taking into account 
the presence of H pylori infection. In the following chapter I will review the 
effect of H pylori infection on gastric acid secretion which is likely to be the key 
factor in the pathogenesis of ulcer disease.
CHAPTER THREE
HELICOBACTER PYLORI COLONISATION 
AND ALTERATIONS IN GASTRIC ACID 
SECRETION
■  ^
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It Is essential to realise that H pylori infection affects gastric physiology 
differently in the acute and chronic stages. Very little is known about the 
sequence of events following acute infection of H pylori and some evidence 
exists to suggest that the infection may turn off the production of acid for a 
short period. However, much work needs to be done in this field before we 
can make any generalisation. It is recognised, however, that the type of 
gastritis which is associated with ulceration both in the stomach and 
duodenum is the chronic form, the effects of which are discussed below.
3.1. HPVLOR/AND GASTRIN
Numerous studies have shown that H pylori infection is associated with 
increased basal, meal stimulated and bombesin/gastrin releasing peptide 
stimulated gastrin concentrations which rapidly return to normal following 
eradication of the infection (96-101). The degree of hypergastrinaemia caused 
by H pylori is the same in DU patients and healthy volunteers (97). The 
elevated gastrin level associated with H pylori infection is due to an increase in 
the biologically active Gastrin-17 (G17) form of the hormone (102). G17 is 
mainly produced in the gastric antrum whereas G34 is mainly produced in the 
duodenum. The increase in the G17 form is consistent with H  pylori 
predominantly affecting the antral mucosa. In addition, G17 is the main gastrin 
which increases in response to eating (102), and this is consistent with H pylori 
associated hypergastrinaemia being most marked postprandially.
.   __           . . . .  ._ .
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3.2. MECHANISM OF H PYLORI ASSOCIATED
urease activity by 36 hours of triple therapy but again could not demonstrate
i
HYPERGASTRINAEMIA----------------------------------------------------
The mechanism by which H  pylori infection causes increased antral Igastrin release is unclear. Levi et al postulated that the ammonia produced by 
the high bacterium urease activity might raise antral surface pH and thereby 
prevent the physiological inhibition of gastrin release by intragastric acid (103).
McColl et al in Glasgow have performed a number of studies in order to test 
this very plausible hypothesis. In the first study, H pylori ammonia production 
was increased in vivo by the intragastric infusion of urea to infected subjects, 
but found no change in the serum gastrin (104). Graham et al performed a 
similar study with the same result (100). Nujumi et al also assessed the effect 
of inhibiting H  pylori urease activity in vivo by the oral administration of 
acetohydroxamic acid to infected subjects. Despite inhibiting bacterial urease 
activity by more than 80%, no change could be detected in serum gastrin
#
I(105). In a further study, the same authors completely suppressed H pylori 
any fall in either basal or meal stimulated gastrin concentrations (106).
If H pylori v/ere raising gastrin by its ammonia production blocking the 
inhibiting effect of intragastric acid, then H pylori associated hypergastrinaemia
should be most marked at low intragastric pH, at least In the absence of acid.
Iîii
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However, Chittajallu et al found that H pylori infection raised gastrin by a 
similar percentage in the presence and absence of gastric acid (107).
Likewise, Moss et al (108) and Karnes et al (109) found that H pylori infection 
was associated with a similar percentage increase in gastrin at pH 5.5 and pH 
2.5.
Studies to date, therefore, do not support the hypergastrinaemia being 
secondary to bacterial ammonia interfering with the acid inhibitory control of 
gastrin release.
Another possible cause of H pylori induced hypergastrinaemia is that it is 
a compensatory response to the infection reducing gastric acid secretion. 
There is some evidence that acute H pylori infection may cause 
hypochlorhydria, and in some subjects this could persist and thus produce 
reflex hypergastrinaemia. Both McColl et al and Calam et al have studied the 
acid response to increasing doses of gastrin in DU patients before and 
following eradication of H pylori and have found no change in parietal cell 
sensitivity (110,111). This excludes the increased gastrin being secondary to 
the infection impairing parietal cell function in patients with DU. However, there 
are no data on the effects of chronic infection on parietal cell function in non- 
DU subjects.
I
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The release of gastrin by the antral mucosa is under inhibitory control by 
somatostatin release from the antral D cells. The hypergastrinaemia could 
therefore be secondary to a relative deficiency of somatostatin. As 
somatostatin mainly exerts its effects locally in a paracrine fashion, it is 
necessary to look at the concentrations of the hormone in the mucosa rather 
than in the serum. Kaneko et al reported reduced immunoreactive/ 
somatostatin concentrations in gastric mucosal biopsies of patients with H  
pylori infection (112). However, a wide variety of upper gastrointestinal 
disorders were included in the study, and it is difficult to be sure whether the 
changes in somatostatin were related to the infection, to specific 
gastrointestinal disorders or to drug therapy. However, a significant correlation 
was noted between the severity of chronic inflammation and degree of 
depletion of somatostatin. In a study of 18 DU patients. Moss et al reported a 
rise in antral mucosal somatostatin/immunoreactive cell density at four weeks 
following eradication of H  pylori infection (113). In a similar study in ten such 
patients they noted a rise in antral mucosal somatostatin mRNA at four weeks 
following eradication of the infection (113). Recently, Graham et al studied D 
cell numbers in volunteers with and without H pylori and in DU patients before 
and following eradication of the infection. There was a trend towards reduced 
D cell numbers in the infected, healthy volunteers, but this did not reach 
statistical significance. In addition, there was no difference in D cell numbers 
between patients and volunteers or between DU patients before and following
_____________ _ _ ________ ___________  __  . ............................................ _ ..........................
61
H pylori eradication (114). At present, therefore, the mechanism of H pylori 
induced hypergastrinaemia remains unclear.
3.3. EFFECT OF HPYLOR/ASSOCIATED 
HYPERGASTRINAEMIA ON ACID SECRETION
Gastrin is generally accepted to be the major mediator of the gastric 
phase of acid secretion (115). The fact that H  pylori increases biologically 
active gastrin, together with the finding in DU patients that this is not 
accompanied by any reduction in parietal cell responsiveness to gastrin, 
suggests that the infection should be causing significantly increased acid 
secretion. A  number of studies have examined acid secretion by a variety of 
methods and these are discussed below.
3.3.1. Effect on Basal Acid Output
There are only a few adequately controlled prospective studies 
examining the effect of H  pylori on basal acid output. There are only a few  
adequately controlled prospective studies examining the effect of H pylori on 
basal acid output. Montbriand et al studied basal acid output in ten patients 
with functional dyspepsia before and following suppression of H pylori. There 
was no statistically significant change, but 8 of the ten did show a fall.
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suggesting that larger numbers might have produced a significant result (116). 
Levi et al did not observe any fall in basal acid output in ten DU patients 
examined after four weeks of triple therapy (117). However, in a more recent 
study the same group did observe a significant fall in a group of nine DU 
patients examined at four weeks following completion of eradication therapy 
(111).
The above studies indicated that H  pylori might be increasing basal acid 
output, but that larger studies were required to clarify the question. The effect 
of H pylori and its eradication on basal acid output in health and disease is one 
of the aspects investigated in this thesis and will be discussed later.
3.3.2. Effect on Maximal Acid Output
There are few adequately controlled studies examining the effect of H  
pylori infection on maximal acid output. The only clear message is that 
eradication of H pylori infection does not cause any early reduction In maximal 
acid output in DU patients (116,117). There is a need for well controlled 
studies with adequate numbers of patients comparing DU patients and healthy 
volunteers with and without H pylori. In addition, studies are required of the 
longer term effects of eradicating H  pylori on maximal acid output.
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3.3.3. Effect on Intragastric Acidity and 24h pH
In 1988, McColl et al examined intragastric pH by means of in situ 
electrodes In twelve DU patients before and one month following eradication of 
the infection (118). There was no overall change in the median intragastric pH. 
However, the authors noted that there was a significantly greater rise in pH in 
response to the buffering effect of the meal following eradication of the 
infection. This was consistent with reduced acid secretion in response to the 
meals. However, when a smaller number of subjects were re-examined seven 
months later, the changes were no longer significant (96). Smith et al found no 
difference in median 24 hour intragastric acidity in a retrospective analysis 
comparing eight H pylori seropositive and eighty-seven seronegative young 
healthy volunteers (119). Eradication of the infection in the eight subjects did 
not produce any change in intragastric acidity when re-examined one month or 
six months later (99).
At present, therefore, the effect of H pylori on intragastric acidity remains 
unclear. One problem with intragastric pH is that it is a relatively insensitive 
method of assessing changes in gastric acid secretion. This is partly due to its 
poor reproducibility. Fimmel et al found that the day to day variation in median 
24 hour pH, using in situ electrodes, was in the region of 1 pH unit (120). This 
variability can be explained by the fact that in situ electrodes can move within 
the gastric lumen and daytime pH varies by approximately 1 pH unit between
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the antrum and body (121). In addition, alkaline reflux of duodenal contents or 
close contact between the electrode and mucosa can cause intermittent and 
marked rises in pH through the night (121). Day to day variations in the order 
of 1 pH unit are a major problem, as this represents a ten-fold variation in 
hydrogen ion concentration. Another weakness of intragastric pH or acidity 
studies is that they only assess hydrogen ion concentration and not the volume 
of gastric juice secreted, which is a major determinant of acid output. These 
problems associated with intragastric acidity measurements are exemplified by 
the fact that ranitidine 300mg, which markedly inhibits gastric acid secretion, 
may only increase median 24 hour intragastric pH in DU subjects from 1.1 to 
1.4, i.e. an increase of only 0.3 pH units (122).
In view of the insensitivity of intragastric pH studies, the lack of 
consistent change following eradication of H pylori in the small number of 
subjects examined to date in no way excludes a significant change in acid 
secretion.
From the above discussion we can conclude that H  pylori infection is 
significantly affecting the regulation of gastric acid secretion. Subjects with the 
infection have exaggerated basal and meal stimulated gastrin concentrations 
but the effect of this on acid secretion is still not clear. Methods available 
for
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studying gastrin mediated acid secretion have yielded conflicting results and 
the effect of eradicating the infection on acid secretion remains controversial.
'Z T I'-""»
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AIMS OF THE THESIS
The main aim of this thesis was to clarify the role of H  pylori infection in the
(1) To devise a new approach to the study of gastrin mediated acid secretion
regulation of gastric acid secretion in man. The objectives were as foiiows:
f t
through the use of the substance gastrin releasing peptide (GRP). The
Idescription and reproducibility of this test are presented in chapter four.
(2) To study basal and GRP stimulated gastrin and acid secretion in healthy
■ftvolunteers with and without H  pylori infection and in DU patients with the 
infection.
(3) To study the effect of eradicating H pylori infection on basal and GRP Istimulated gastrin and acid secretion in healthy volunteers and DU patients. 1(4) To study the mechanism of exaggerated acid secretion seen in DU 
patients and the role of H pylori infection in this.
(5) To study the effect of treatment with H2 antagonists on basal and GRP 
stimulated gastrin and acid secretion in healthy volunteers.
(6) To study the effect of H pylori infection on basal and GRP stimulated Igastrin and acid secretion in patients with non ulcer dyspepsia.
Î
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CHAPTER FOUR
DESCRIPTION & REPRODUCIBILITY DATA
■»
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:STHE GRP TEST: A NEW CLINICAL
TEST OF GASTRIC ACID SECRETION :
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4.1. INTRODUCTION
The first project undertaken in my thesis was to devise a new clinical test 
to enable us to study gastrin mediated acid secretion without using a meal as 
the stimulus. Our knowledge of gastric physiology was helpful in that respect 
as we were aware of the central role played by a substance called gastrin 
releasing peptide (GRP) in the regulation of gastric acid secretion. GRP is 
present in nerves throughout the Gl tract and in particularly high
concentrations in the antral mucosa of the stomach (123,124). The 
neuropeptide plays a key role in the mediation of meal-stimulated acid 
secretion ('•25) Peptone in the stomach stimulates intramural neurones to 
release GRP which then stimulates the G cells in the antral mucosa to release 
gastrin which in turn stimulates the parietal ceils to secrete acid. Acid secretion 
in response to GRP is thus a result of the combined functional response of the 
antral and oxyntic mucosae. GRP also activates inhibitory pathways involved 
in the regulation of acid secretion (126-128). GRP was therefore chosen as the 
stimulus to study gastrin mediated acid secretion.
The present study was undertaken to assess the reproducibility of this new 
test before using it to study the effect of H pylori infection on gastric acid 
secretion.
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4.2. PATIENTS AND METHODS
Forteen subjects (9 males) were studied. Mean age was 35 years (range 
24-53). Five had chronic duodenal ulcer disease with H pylori Infection, 4 were 
healthy volunteers with H pylori infection, and 5 were healthy volunteers 
without H pylori infection. Duodenal ulcer patients were asked to stop 
antisecretory therapy at least four weeks prior to the secretory studies. None of 
the healthy volunteers was on any medication and none reported any major 
gastrointestinal symptoms. H pylori infection was confirmed in the DU patients 
by microscopic examination of antral biopsies, rapid urease test (CLO test) on
antral biopsy and by the urea breath test as described below. In healthy
volunteers H pylori status was determined by the urea breath test.
Each subject had their basal and GRP-stimulated acid secretion assessed 
under identical conditions on two separate days (day 1 and day 2). The 
investigator was blind to the result of the first test. The mean time interval 
between days 1 and 2 was 3.4 weeks (range 1-26). DU patients remained off 
antisecretory therapy until the completion of the reproducibility studies. Gastrin 
samples from the two study days for each subject were assayed in the same 
batch.
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The urea breath test
This is a standard test in our laboratory and has been validated and used iextensively. It involves giving a test dose of 0.4 MBq of C urea in 0.3mi water
li
in 25ml water.
I I
The subject is fasted from 21:00hr the previous night. The subject is 
weighed with indoor clothes and shoes on and then asked to clean their teeth 
without swallowing any water and discarding all rinsings into running water in 
the basin. The subject is shown how to give a “Breath Sample” and this Is 
taken as “Base”. A  test meal consisting of 200ml of Ensure is given followed by 
the test dose, then two rinsings of 25ml water. This is taken as time zero. The Isubject is then asked to re-clean their teeth as above and then give breath 
samples every 10 minutes till the end of the test. For most studies we use the 
short 30 minute breath test and take the 20 minute sample count as the 
important result. Counts above 40 are regarded as positive. Those below 20 
are regarded as negative. Those which fall between 20 and 40 are treated as 
equivocal.
I
i
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The GRP Test
All subjects reported at 09:00am following a 12 hour fast. A  nasogastric 
tube (Anderson Inc., New York ) was swallowed and its position in the
dependent part of the stomach checked by the water recovery test. This
involved aspirating the contents of the stomach until no contents could be
1I
recovered. Sixty ml of warm water were then infused into the stomach through 
the nasogastric tube over a period of 30 seconds. After one minute the water 
was aspirated and its volume checked. Recovery was judged satisfactory if 
more than 95% of the 60 mi were recovered. After emptying the stomach, 
intermittent suction was applied using an intermittent suction unit (Ohmeda,
Columbia, U.S.A.) which applies suction for 20 seconds in each 32 second 
cycle. Three 15 min collections were obtained basally and at each of the IP
following rates of I.V. infusion of GRP: 10 and 40 pm ol.kg"\h'\ Blood samples
'.1-
l iwere collected every 15 minutes for gastrin determination and the plasma 
stored at -20 °C.
fti
■i
The volume and pH of each gastric juice collection was recorded and its 
hydrogen ion concentration measured by titration with 0.1N NaOH to pH7 
using an autotitrator (Radiometer ETS 822).
i;
I
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Basal acid output was calculated by taking the mean of all three samples 
prior to GRP infusion. Acid output for each GRP infusion rate was calculated 
by taking the mean of the second and third 15 min collections.
Gastrin was measured by radioimmunoassay using antiserum R98 which
has a sensitivity of 5ng/l ('•29) The basal gastrin value for each subject was 
determined by taking the mean of the three samples obtained prior to the start 
of GRP infusion. The gastrin value at each infusion rate of GRP was 
determined by taking the mean of the values at 30 and 45 minutes of each 
infusion.
Preparation of GRP
GRP was purchased from Cambridge Research Biochemicals (Cheshire, 
England) in Im g aliquots of freeze-dried lyophilised powder. Subsequent 
preparation was undertaken by the Western Infirmary Pharmacy Department 
under sterile conditions. Each aliquot was made up into a 10ml stock solution 
by dissolving in sterile water and 0.1ml of 50% acetic acid soiution was added 
to stabilise into solution. Vials containing lOOiag of GRP in Im i of solution were 
prepared and stored at -80 °C until the day of each study. For each study the 
content of each vial was further diluted in 0.9% NaCI soiution. The peptide 
solution was filtered through a low protein binding bacterial filter (Gelman
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Sciences, Northampton, England) before the final concentrations of the 
peptide were made up.
Statistics
the between day coefficient of variation for both gastrin and acid at basal, 10
■
I
■i
I»
I
Reproducibility of the GRP test was assessed by calculating estimates of
■is{
and 40pmol.kg'\h'^ of GRP. The study was approved by the Western Infirmary
Ethical Committee.
Î!
I
:;ÿj
■I
4.3. RESULTS
Reproducibility data is presented for basal gastrin and acid secretion and 
for gastrin and acid secretion at 10 and 40pmol.kg \h'^ of GRP infusion. II
Basal
The mean basal gastrin concentration was 49ng/l on day 1 (range: 22-115) 
and 46ng/l on day 2 (range: 12-125)(Fig.4.1.a). The mean basal acid output 
was 4.3mmol/h on day 1 (range: 0.5-13.2) and 4.4mmol/h on day 2 (range: 0.4- 
12))(Fig.4.1.b).
The coefficient of variation for gastrin was 29% and for acid 32%.
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GRP ( 1Qpmol.kg'\h"^ )
The mean gastrin concentration at 10pmol.kg'\h'^ of GRP was 133ng/l on 
day 1 (range: 18-400) and 127ng/l on day 2 (range: 20-250)(Fig.4.2.a). The 
mean acid output at 10pmol.kg'\h'^ of GRP was 14.7mmol/h on day 1 
(range1.5-51,9) and 14.8mmol/h on day 2 (range: 2 .4-56.1)(Fig.4.2.b). The 
coefficient of variation for gastrin was 27% and for acid 11%.
GRP (40pmol.kq \h~  ^ )
The mean gastrin concentration at 40pmol.kg \h   ^ of GRP was 191ng/l on 
day 1 (range: 30-600) and 195ng/l on day 2 (range: 33-570)(Fig.4.3.a). The 
mean acid output at 40pmol.kg'\h'^ of GRP was 21.8mmol/h on day 1 (range: 
1.0-58.8) and 22.0mmol/h on day 2 (range: 0.9-64)(Fig.4.3.b). The coefficient 
of variation for gastrin was 19% and for acid 6%.
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4.4. DISCUSSION
■Bî
g
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Gastrin releasing peptide (GRP) is a 27 amino acid peptide which has 
been detected in neurones throughout the gastrointestinal tract (123) |t acts
exclusively as a neurotransmitter substance (124) whose main function in the 
stomach is mediation of gastrin release from antral G cells. The release of 
gastrin in response to food in the stomach has been shown to be mediated by 
GRP neurones (125) |n addition to stimulating gastrin release GRP is known 
to stimulate the release of other gastrointestinal regulatory peptides in man 
including cholecystokinin, gastric inhibitory peptide, vasoactive intestinal
peptide, neurotensin, enteroglucagon and somatostatin (126-128) which exert 
an inhibitory control on gastrin release and acid secretion. GRP has thus 
emerged over the last few years as perhaps the most central neurotransmitter 
involved in the release of antral regulatory peptides.
The GRP test of acid secretion has several attractive qualities. The first is 
its ability to stimulate acid secretion through release of endogenous gastrin 
allowing the simultaneous assessment of the release of gastrin by the antral
amucosa and the acid secretory response of the oxyntic mucosa to the 
endogenous gastrin. The second is that GRP also stimulates the release of 
gastric inhibitory peptides such as somatostatin and cholecystokinin and in this 
way simulates the response to eating. Thirdly, the GRP test allows the study of
»
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administered it on 300 separate occasions to 150 individuals with no adverse 
reactions. In 25 individuals we have administered GRP in a dose up to 
400pmol.kg'Vh"^ (i.e. 10 times higher than the dose used in this study) without
■'ill
: |
gastrin-mediated acid secretion without the technical difficulties associated 
with the presence of food within the stomach.
The results of our reproducibility studies indicate that both arms of the test,
Ii.e. the gastrin and acid secretion responses, are highly reproducible at both 
concentrations of GRP employed. W e recommend that GRP should be used at 
the higher infusion rate of 40pmol.kg‘\h  \  At this rate the reproducibility of 
gastrin and acid secretion was 19% and 6% respectively. This was better than 
reproducibility at the lower infusion rate of lOpmol.kg \h"^ (27% and 11% for
■
gastrin and acid respectively). Another reason for using the 40pmol.kg'\h"' 
infusion rate is that the gastrin levels achieved with this rate are similar to 
those achieved in response to eating a meal.
4IReproducibility was not as high under basal conditions compared to the
Stimulated state and perhaps reflects varying degrees of reflux of alkaline 
duodenal contents into the stomach.
I
Experience to date ( which includes the major part of the work presented in 
this thesis) indicates that GRP has no adverse side effects. W e have
77
any adverse reactions. Sixty subjects have received it on two separate 
occasions and 25 subjects on three separate occasions without evidence of 
allergic reactions. GRP has also been used by several other investigators and 
no adverse reactions reported (101,130,131) Due to the interest raised by our 
use of GRP as a test of gastric secretory function, a commercially available 
preparation of GRP has recently entered the market manufactured by Clinalfa 
AG, Switzerland. Vials containing 50 fxg of human GRP are sold ready for 
clinical use.
The GRP test is a simple, safe, and highly reproducible test of acid 
secretion. It is a powerful new tool for investigating the pathophysiology of 
upper gastrointestinal disorders.
In the following chapters we describe the use of GRP in investigating the 
effect of H pylori infection on the regulation of gastric acid secretion.
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CHAPTER FIVE S
THE EFFECT OF HELICOBACTER PYLORI 
INFECTION ON GASTRIC ACID SECRETION 
IN HEALTHY VOLUNTEERS AND DUODENAL 
ULCER PATIENTS
S
f
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79
5.1. INTRODUCTION
Though gastrin is recognised as the major mediator of meal stimulated acid
'1
It is now well established that Helicobacter pylori is the major acquired 
factor in the pathogenesis of duodenal ulcer disease. The infection is found in 
>95% of DU patients and numerous studies have demonstrated that 
eradicating it markedly lowers the ulcer relapse rate (37-40). The mechanism 
by which this infection which predominantly affects the gastric mucosa 
predisposes to ulceration of the duodenum has been the subject of much 
speculation .
ÎWork carried out in our own unit in Glasgow as well as in other units has 
shown that both DU patients and healthy volunteers with H  pylori have 
increased basal and meal stimulated gastrin concentrations which fall following 
eradication of the infection (95,96,98,99,132). This hypergastrinaemia is due 
to an increase in the biologically active G17 form of the hormone (102).
Studies have also shown that the parietal cell sensitivity to gastrin is 3unaffected by H pylori (110,111) and, therefore, the increased hormone level is
Î
not simply a compensatory response to the infection impairing acid secretion.
■
secretion (115), the effect of H  py/or/-associated hypergastrinaemia on acid
secretion has remained unclear. As discussed in chapter 3 this is largely due
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to the technical difficulty of reliably measuring acid secretion in response to a 
meal. In view of these problems we proceeded to develop the GRP test of acid 
secretion as described in chapter 4. Having assessed the reproducibility of this 
new tool and found it to be highly reproducible, we proceeded to study the 
effect of H pylori infection on acid secretion stimulated by the intravenous 
administration of GRP. This neuropeptide stimulates the G cells in the antral 
mucosa to release gastrin which in turn stimulates the parietal cells to secrete 
acid. This allows the simultaneous assessment of the combined functional 
response of the antrum and body of the stomach. GRP also stimulates the 
release of a variety of other hormones which exert an inhibitory control on acid 
secretion including cholecystokinin, gastric inhibitory peptide, vasoactive 
intestinal peptide, neurotensin, enteroglucagon and somatostatin (128,133). 
Acid secretion in response to GRP is therefore the product of the combined 
effects of these stimulatory and inhibitory control pathways and in this way 
resembles acid secretion in response to a meal.
In this study we examined basal and GRP stimulated acid secretion in 
healthy volunteers with and without H  pylori infection and in DU patients with 
the infection. W e also examined the effect of eradication of H pylori on basal 
and GRP stimulated acid secretion in healthy volunteers and DU patients and 
proceeded to examine the long-term effects of eradication of the infection on 
acid secretion in DU patients.
     _ ..... . :
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S.2. PATIENTS AND METHODS !
ï
Twenty five H pylori positive patients (17 maies) with endoscopically
:confirmed chronic duodenal ulcer disease, 25 H pylori positive healthy
Ivolunteers (17 males), and 25 H  pylori negative healthy volunteers (17 males) 
were studied. The three groups were matched for age and body weight. There 
were 20 smokers in the DU group and 6 in each of the other 2 groups.
.
Duodenal ulcer patients were asked to stop any antisecretory therapy at least Ifour weeks prior to the secretory studies. None of the healthy volunteers was 
on any medication and none reported major gastrointestinal symptoms. H  
pylori infection was confirmed in the DU patients by microscopic examination of
antral biopsy, rapid urease test (CLO test) on antral biopsy and by 14q  urea
breath test. In healthy volunteers, H  pylori status was determined by the 14q  
urea breath test.
  _ _   _ _     .   .
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Secretory studies
§
All subjects reported at 09:00h following a 12 hour fast. An orogastric tube 
(Anderson Inc., New York) was swallowed and its position in the dependent 
part of the stomach checked by the water recovery test. After emptying the
| -
J
stomach, intermittent suction was applied using an intermittent suction unit
■il
(Ohmeda, Columbia, U.S.A.) as described in chapter 4. Three 15 minute
collections were obtained basally and at a GRP infusion rate of both 10 and 40
'■ I
pmol.kg"1.h“1. Blood samples were collected every 15 min for gastrin
I
determination and the plasma stored at -20 °C. The secretory studies were all 
performed with the investigator blind to the subjects' H pylori status.
The preparation of GRP is described in chapter 4. The volume and pH of
■each gastric juice collection were recorded and its hydrogen ion concentration 
measured by titration with 0.1M NaOH to pH 7 using an autotitrator
I(Radiometer ETS 822). ■I.
Basal acid output was calculated by taking the mean of all three 15 min 
samples prior to GRP infusion. Acid output for each GRP infusion rate was 
calculated by taking the mean of the second and third 15 min collections.
i
'I 
1
The measurement of gastrin is described in chapter 4.
3■it.
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Eradication of H pylori
Following the above secretory studies, 18 DU patients and 15 healthy 
volunteers with H  pylori infection were treated with tripotassium 
dicitratobismuthate 120mg t.i.d., metronidazole 400mg ti.d . and amoxycillin 
500mg t.i.d. for 3 weeks. One month following completion of this therapy their
14c urea breath test was repeated to determine H  pylori status. Their 
secretory studies were also repeated at this point. Ten of the treated DU 
patients were also re-examined one year following triple therapy with repeat 
14c urea breath test and secretory studies. The ten DU patients re-examined 
at one year consisted of those whose acid output remained elevated at one 
month following eradication of H  pylori.
Statistics
Statistical analysis of unpaired data was performed using the Mann- 
Whitney U test and of paired data using the Wilcoxon test. A 'p' value of <0.05
was taken as significant. Correlation of gastrin concentrations and acid output
■iwas assessed using linear regression analysis.
IThe study was approved by the Western Infirmary ethical committee.
. 4 : -  -:" 4 .  _ .................................... _
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5,3, RESULTS
The repeat 14q urea breath test at one month after completion of the triple 
anti-H pylori therapy indicated eradication of the infection in 16 of the 18 DU 
patients and 14 of the 15 healthy volunteers. All ten DU patients who were re­
examined at one year post-eradication therapy remained free of the infection.
:g;
Basal Gastrin
The basal gastrin concentration (ng/l) was similar in the H pylori positive 
healthy volunteers (median=45, range: 10-90) and H pylori positive DU 
patients (60, range: 22-175) and both were higher than the H pylori negative 
healthy volunteers (32, range: 15-50)(p<0.005 for either) (fig.5.1.). One month 
following eradication of Hpy/or/the median plasma gastrin concentration in the 
16 DU patients fell from 50 (range: 22-150) pre-eradication to 40 (range: 12- 
70)(p<0.01 versus pre-eradication) and in the 14 healthy volunteers from 48 
(range: 10-90) to 32 (range: 7-110)(p<0.02 versus pre-eradication). At one 
month post-eradication both values were not significantly different from the 
value in the H pylori negative healthy volunteers.
The median basal gastrin concentration in the 10 DU patients who were 
followed up for one year was 52ng/l (range: 22-150) pre-eradication and fell to
BASAL GASTRIN
CONCENTRATION (ng/l)
200
175
150 -
125 -
100
75
50 -
25
0
ooo o
o oo ooo o
0 8 0 8 0  -O  o ^ o o o  o
• • •
# #
ee
o
0 0oo
° § o
o :
o
» # #
#
I
I
o
8 0
oo
0 0o
oo
o
0 0
o
0 0
8oo
H P +ve  D.U. D.U.
D.U. Patients Patients
Patients 1/12 Post - 1 Year Post -
Eradication Eradication
THP -ve HP +ve Healthy
Healthy Healthy Volunteers
Volunteers Volunteers 1/12 Post-
Eradlcalion
FIG. (5.1.)
Basal gastrin concentrations in healthy volunteers and DU patients of varying 
H pylori status ( #  indicates H pylori positive). Compared to the H  pylori 
negative healthy volunteers, basal gastrin values are increased only in the H  
pylori positive healthy volunteers (p<0.005) and the H  pylori positive DU 
patients (p<0.005).
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36 (range: 12-68) at one month post-eradication (p<0.01) and was similar one 
year later (median = 40, range: 15-75)(fig.5.1.).
Basal Acid Secretion
I
The median basal acid output (mmol/h) was higher in the H  pylori positive 
(2.9, range: 0.5-13.3) compared to negative (1.8, range: 0.5-7.9) healthy 
volunteers (p<0.05) (fig.5.2.). In addition, it was increased in the H  pylori 
positive DU patients (6 .6 , range: 2.6-25.8) compared to both the H  pylori 
negative healthy volunteers (p<0.0001) and H  pylori positive healthy 
volunteers (p< 0.001). Eradication of H pylori lowered the median basal acid 
output in the 16 DU patients from 7.2mmol/h (range: 3.1-25.8) pre-eradication 
to 3.3 (range: 1.2-11.3) at one month post-eradication (p<0.01 versus pre- 
eradication), representing a median reduction of 50% (20% - 80%). However,
at this time point post-eradication the basal acid output in the DU patients was 
still increased compared to the H pylori negative healthy volunteers (p<0.01). 
At one month following eradication of H pylori in the 14 healthy volunteers their 
median acid output was 1.8 (range: 0.2-13.1) which was not significantly 
different from their pre-eradication value (median = 2.0, range: 0.5- 
13.5)(p=0.8). The basal acid outputs in the two DU patients and the one 
healthy volunteer in whom H pylori infection was not eradicated were similar 
before ( 3.7, 6.3, and 1.2) and following (4.8, 6.1 and 2.4 respectively) triple 
therapy.
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FIG. (5.2.)
Basal acid output in healthy volunteers and DU patients of varying H pylori
h uh  ^ *, ^  Py/O" positive). Compared to the H pylori negative hea thy vo unteers, basal acid output is increased only in the H pylori positive 
healthy volunteers (p<0.05), H pylori positive DU patients (p<0.0001) and DU
patients one month post eradication (p<0.01).
86
The median basal acid output in the 10 DU patients who were followed up 
for one year was 8.1 mmol/h (range: 3.1-25.8) pre-eradication and fell to 
4.5mmol/h (range: 1.2-11.3)(p<0.01 versus pre-eradication) atone month post­
eradication and this fell further to 2.5mmol/h (range: 0.0-5.1) at one year post­
eradication (p< 0.04 versus one month post-eradication) when it became 
similar to H pylori negative healthy volunteers (fig.5.2.).
Correlation Between basal gastrin and basal acid
In H pylori positive DU patients there was no correlation between basal
gastrin and basal acid output (r=0.27, p< 0.2). Correlation between basal
gastrin and basal acid output was stronger in the H pylori positive healthy 
volunteers but still failed to reach statistical significance (r=0.37, p<0.07).
Gastrin Response to GRP
At the GRP infusion rate of 40pm ol.kg-i.h-i the median gastrin 
concentration (ng/l) was increased to a similar level in the H pylori positive 
healthy volunteers (238, range: 38-563) and H pylori positive DU patients (255, 
range: 90-600) and each was higher than that of the H pylori negative healthy 
volunteers (70, range: 28-157) (p<0.002 for each)(fig.5.3.). At one month 
following eradication of H pylori the median gastrin concentration in response
to GRP 40pmol.kg”1.h"1 in the 16 DU patients fell from 270 (range: 95-600)
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FIG. (5.3.^
Gastrin concentrations in response to stimulation with GRP (40pmol.kg-1.h‘ 1) ( e indicates H pylori positive). Compared to H  pylori negative healthy 
volunteers gastrin concentrations are increased only in the H  pylori positive 
healthy volunteers (p<0.002) and in H pylori positive DU patients (p<0 002).
pre-eradication to 84 (range: 23-200)(p<0.01 versus pre-eradication). In the 14
Ihealthy volunteers eradication of H  pylori lowered the median gastrin 
concentration in response to GRP 40pmol.kg”1.h"1 from 249 (range: 35-563)
The median gastrin concentration in response to 40pmo!.kg“1.h"1 GRP in 
the 10 DU patients who were followed up for one year was 278ng/l (range: 95- 
600) pre-eradication and fell to 90 (range: 30-200) at one month post-
Acid Response to GRP
At GRP 40pmol.kg“1.h"1 the median acid output (mmol/h) in the H pylori 
positive healthy volunteers (19.0, range: 1.0-38.3) was approximately 3 times
pre-eradication to 58 (range: 20-330) at one month post-eradication (p<0.01
versus pre-eradication). At one month post-eradication the values in both the 
DU patients and healthy volunteers were similar to those of the H pylori 
negative healthy volunteers (fig.5.3.).
eradication and was similar one year later (78, range: 25-180)(fig.5.3.).
i
The gastrin concentration in the five groups of subjects at the GRP 
lOpmol.kg"’ .h"l infusion rate showed the same pattern of response to that
■i'l
seen in response to GRP 40pmol/kg/h. W e chose to present the results of the
individual data points for the 40pmol.kg“Th"^ GRP rate as the gastrin levels 
stimulated by this are closer to those seen following a meal.
    _ . ..................................
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that of the H  pylori negative healthy volunteers (6.3, range: 2.8- 
20.9)(p<0.001)(fig.5.4.). At this infusion rate the median acid output in the H  
py/or/positive DU patients was 39.1 (range: 17.9-64) which was approximately 
twice that of the H  pylori positive healthy volunteers (p<0.005) and 6  times that 
of the H  pylori negative healthy volunteers (p<0.001). In the 16 DU patients 
whose H pylori infection was eradicated their median acid output fell from 39.6 
(range: 18.9-64) pre-eradication to 16.6mmol/h (range: 3.9-24)(p<0.01) at one 
month post-eradication but was still higher than the H pylori negative healthy 
volunteers (p<0.005). In the 14 healthy volunteers who were eradicated of the 
infection the median acid output was 15.6mmol/h (range: 1.0-38.3) pre­
eradication and this fell to 6.7 (range: 0.8-21.0) one month post-eradication. 
Acid secretion did not fall in the two DU patients and the one healthy volunteer 
in whom the infection was not eradicated being 17.9, 39 and 15.1 mmol/h 
before treatment and 28.4, 37.6 and 15.0 mmol/h respectively at one month 
following treatment.
The median acid output in response to 40pmol.kg"1.h"1 GRP in the 10 DU 
patients who were followed up for one year was 39.6mmol/h (range: 21.5-57) 
pre-eradication and fell to 19.0mmol/h (range: 11.3-24)(p<0.01 versus pre­
eradication) at one month post-eradication and then fell further to 8 .0 mmol/h 
(range: 5.2-18.6)(p<0.01 versus one month post-eradication) at one year post­
eradication when it became similar to the values of the H  pylori negative
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FIG. (5.4.)
Acid output in response to stimulation with GRP (40pmol.kg“‘^ .h"‘^ )(#  indicates 
H pylori positive). Compared to H  pylori negative healthy volunteers, acid 
output is increased in H pylori positive healthy volunteers (p<0 .0 0 1 ), H  pylori 
positive DU patients (p<0 .0 0 1 ) and DU patients one month post eradication 
P<0 .0 1 ), The ten DU patients who were re-examined at one year post 
eradication were the ten who had the highest acid output at one month post 
eradication.
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healthy volunteers (median = 6.3, range; 2.8-20.9)(p=0.1)(fig.5.4.). The GRP- 
stimulated acid output In this group of ten DU patients has fallen by a median 
of 78% (range: 60% - 87%) at one year post-eradication compared to pre­
eradication values. f
ICorrelation Between GRP Stimulated Gastrin and AcidIn H pylori positive DU patients there was no correlation between GRP 
stimulated gastrin concentration and acid output (r=0.12, p= 0.58). In H pylori 
positive healthy volunteers there was significant correlation between GRP 
stimulated gastrin concentration and acid output (r=0.50, p<0.01)(Fig.5.5.).
ACID
OUTPUT
(mmol/h)
r = 0.5 
p < 0.01
Gastrin concentration (ng/l)
F IG . (5.5.)
Correlation between gastrin concentrations and acid output during stimulation 
with GRP (40pmol.kg"1 .h"'*) in the H pylori positive healthy volunteers.
90
5.4. DISCUSSION
output and 3-fold increase In GRP stimulated acid output. The fact that the 
increased acid output resolved fully following eradication of H pylori indicates 
that the infection is the cause of the acid hypersecretion.
The increased acid secretion in the infected healthy volunteers appears to 
be mainly or entirely secondary to increased antral gastrin release. This is 
supported by several observations. The first is the fact that the increased basal 
and GRP stimulated acid outputs were both associated with increased gastrin
i
■'4 ;
H pylori infection is common in the general population and its prevalence 
increases with age (45). It has been recognised for some time that the 
infection causes chronic inflammation of the gastric mucosa (134). In addition, 
numerous studies have shown that the Infection causes increased circulating 
gastrin concentrations (95,96,98,99,132). However, the effect of H pylori 
infection and the accompanying hypergastrinaemia on gastric acid secretion 
has been unclear.
s
The present studies demonstrate that H pylori infection in healthy 
volunteers is associated with an increase in both basal and stimulated acid 
output. Compared with true normal controls (i.e. H  pylori negative healthy 
volunteers), infected healthy volunteers have a 2 -fold increase in basal acid
%I
I
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release. The second is the finding of a significant positive correlation between 
acid secretion and gastrin levels both basally and during GRP. The third is the 
fact that the acid hypersecretion fully resolved at the same time as resolution 
of the hypergastrinaemia, at one month post eradication.
The H pylori positive healthy volunteers also differed from the uninfected 
healthy volunteers in showing a much wider range of acid secretion. This was 
particularly marked during GRP stimulation when the acid output in 24 of the 
25 H pylori negative healthy volunteers showed a 4-fold range (from 2.8-10.9) 
whereas the H pylori positive healthy volunteers were widely scattered 
between 1.0 and 38.3 representing a 38-fold range. This wide range in acid 
secretion in the H pylori positive healthy volunteers could be explained by the 
wide variation in the degree of hypergastrinaemia caused by the infection in 
different subjects.
considered to be true normals will have had disturbed gastric function due to H  
pylori infection. It is important that all future studies of human gastric function 
include normal controls who are H  pylori negative. As shown in our present
The finding that H pylori infection markedly alters gastric secretory function 
in apparently healthy volunteers has important implications for gastrointestinal 
research. It means that much of the large literature on human gastric
'physiology and pathophysiology is flawed as a substantial proportion of those
__
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studies, true normal controls have a tight range of gastric secretory function 
which will facilitate future research.
In the DU patients, both basal and GRP stimulated acid outputs were 
increased 6 -fold compared to H  pylori negative healthy volunteers. The fact 
that acid secretion in DU patients is so markedly increased in comparison to 
the true physiological range strongly supports a role for acid in the 
pathophysiology of DU disease.
The basal and GRP stimulated acid outputs of the DU patients were both 
twice those of the H pylori positive healthy volunteers, despite the two groups 
having similar gastrin levels both basally and in response to GRP. This 
indicates that the DU patients are producing twice as much acid as the H pylori 
healthy volunteers for the same level of gastrin stimulation.
Eradicating H pylori infection in the DU patients reduced their basal and 
GRP stimulated gastrin levels to normal values within one month and this was 
associated with a 50% fall in basal acid output and a 6 8 % fall in GRP 
stimulated output. However, at this time point the basal and GRP stimulated 
acid outputs were still twice normal (i.e. H pylori negative healthy volunteers 
values). This again demonstrated that the DU patients were producing twice as 
much acid secretion as the non-DU subjects with equivalent gastrin levels.
■I
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response compared to their 3 fold exaggerated response may be explained by 
the fact that we had a group of H pylori negative volunteers to define true
' 1
These findings indicate that the 6 -fold increase in acid secretion in the DU 
patients is due to the combination of two factors: (1) Increased antral gastrin II
release and (2) An exaggerated acid response to gastrin stimulation. The first 
factor is the same as that noted in the H pylori positive healthy volunteers and 
resolves within one month of eradicating the infection. The second factor is a 
specific feature of the DU patients and it persisted at one month post Ieradication.
It is interesting to compare our findings using GRP with those of
#
Hirschowitz et al using the closely related peptide bombesin which exerts 
similar biological effects (133). They studied the gastrin and acid response in 
DU patients and healthy controls prior to the recognition of H pylori. Acid 
output to bombesin was increased approximately 3 fold in the DU patients. The aexaggerated acid response was again due to the combination of two defects:
$
(1) increased antral gastrin release and (2 ) an increased acid response by the
oxyntic mucosa to gastrin stimulation which was most apparent at higher 
bombesin infusion rates. The findings by Hirschowitz et al are thus very similar Ito our own findings. The fact that we have found a 6  fold exaggerated acid
I
a«
anormal whereas a proportion of the "normals" in the earlier study would have
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basal acid output fell by a further 39% over the year and again became 
equivalent to that of the H  pylori negative healthy volunteers. This further fall in 
acid secretion was not accompanied by any further fall in gastrin and therefore 
represented resolution of the second factor i.e. the increased acid response to
Though the eventual resolution of the second defect in the DU patients 
indicates that it is not a genetic defect, its precise explanation is unclear. It 
may represent trophic effects of H  py/or/-induced hypergastrinaemia on the 
oxyntic mucosa. Even physiological concentrations of gastrin exert trophic 
effects on the oxyntic mucosa (135) and long-term exposure to the modestly
had an exaggerated response due to unrecognised H pylori infection. Our own 
studies extend the work of Hirschowitz et al by showing that the defects in acid
regulation are secondary to H  pylori and fully resolve following its eradication.
In the present study we were able to examine whether this second factor 
present in the DU patients i.e. the exaggerated acid response to gastrin 
stimulation, represented a genetic factor predisposing to DU disease or was 
another reversible acquired factor. This was done by re-examining the ten DU
patients whose acid output remained elevated at one month post-eradication
of H pylori. Within one year their acid output fell by a further 50% and became 
equivalent to that of the H pylori negative healthy volunteers. Likewise, their
gastrin stimulation.
Ia
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increased levels caused by H pylori could have significant effects. In addition, 
the further increase in gastrin associated with acid-inhibitory therapy could 
increase the trophic effects on the oxyntic mucosa. Such changes would take
several months to resolve following restoration of normal gastrin levels, due to
s
the long half-life of the parietal cell (136,137).
There has been considerable reluctance among clinicians to accept the 
pathogenic role of H pylori in DU disease despite several trials confirming 
markedly reduced ulcer relapse rates following eradication of the infection 
(37-40). Part of this reluctance can be explained by the conceptual difficulties 
in understanding how an infection of the stomach can predispose to ulceration 
of the duodenum. Our finding that basal and GRP stimulated acid outputs are
increased 6 -fold in duodenal ulcer disease and that the acid hypersecretion |(
eventually fully resolves following eradication of H pylori provides a scientific
explanation for the role of the infection in DU disease. When permanent 
resolution of the marked acid hypersecretion can be achieved by a single
:
course of H  py/on eradication therapy, there is little justification to continue to 
treat DU patients with repeated courses of expensive acid suppressive 
therapy.
i'm
There are also clinical implications from our finding that H pylori infection is saccompanied by a 3-fold increase in acid secretion in the general population.
y  - - ' ■ ' ' y- ' ' _____________ ... _   . . . . _____  . ...........................
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At present, acid inhibitory agents are prescribed to patients who have a wide 
variety of diseases other than duodenal ulceration in which reduction of acid 
secretion is thought to be of benefit. A  high proportion of such patients will 
have H pylori infection and permanently lowering their acid secretion by 
eradicating the infection could be helpful in their long-term management.
One of the paradoxes associated with H pylori infection is the fact that it is 
on the one hand associated with DU disease which is a disorder of acid 
hypersecretion and, on the other hand, associated with gastric cancer (31-33) 
which is a disease of acid hyposecretion (138). This may be explained by our 
finding that H pylori infection is associated with a wide range of abnormalities 
of acid secretion. Indeed, when our H  pylori positive healthy volunteers and 
DU patients are combined, the acid secretion associated with the infection 
ranges from below to many times above the true normal range. Our studies 
indicate that the top of the range is associated with DU disease and it is 
tempting to speculate that those at the bottom end may be the ones at risk of 
gastric cancer. The reason why H pylori infection produces different degrees of 
acid hypersecretion in different subjects is unclear.
In addition to considering the pathophysiological significance of H pylori 
induced disturbances in acid secretion in DU patients and in other diseases, 
one has to consider its importance in the 50% of the world's population who
l iI
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carry the infection but have no apparent Gl disease. In many of the developing 
countries, the prevalence of H pylori is almost 100% and it is acquired in early 
childhood (30,48). This high prevalence raises the possibility that the infection 
could be conferring some benefit in those regions. The major cause of death in 
such countries is enteric infections and gastric acid secretion is an important 
way in which the body defends itself from food borne infections (139). It is 
possible that the increased acid secretion induced by H  pylori infection 
provides protection from more serious enteric infections in the developing 
world.
In conclusion, the fact that acid secretion is increased 6 -fold in DU patients 
suggests that this is likely to be the key pathophysiological defect in DU 
disease. The finding that this increased acid secretion fully resolves following 
eradication of H pylori explains the role of the infection in DU disease. The 
finding that H pylori infection produces a 3-fold increase in acid secretion in 
the general population has major implications for other Gl diseases.
y: :  y--y- ^ y  ^y y-,
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CHAPTER SIX
INVESTIGATION OF THE MECHANISM OF
EXAGGERATED ACID RESPONSE TO GRP
IN DUODENAL ULCER PATIENTS
y-ggyyy.
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6.1. INTRODUCTION
parietal cell mass should resolve following eradication of H pylori and 
resolution of the hypergastrinaemia.
1I*
II
In chapter 5 we observed that GRP stimulated acid output was increased 
3-fold in H pylori positive healthy volunteers and 6 -fold in H pylori positive DU 
patients, compared to H pylori negative healthy volunteers. In addition we
-found that the acid output in the DU patients fell by 6 8 % at one month 
following H pylori eradication but was still twice as high as the H pylori 
negative healthy volunteers despite normalisation of their gastrin
:
.H,.'
concentrations. This exaggerated acid response to GRP seen at one month 
post-eradication fully resolved when the subjects were re-examined one year 
later.
In the present study we have proceeded to investigate the mechanism of
-.y
the exaggerated acid response to GRP seen in the DU patients. It is well 
established that DU patients have a larger parietal cell mass than normal 
subjects. It is likely that part of the exaggerated acid response observed in DU
patients is due to their increased parietal cell mass. This increased parietal 
cell mass might be a result of the trophic effect of H pylori-\n6uce6
.■hypergastrinaemia on the oxyntic mucosa. If this is the case then the increased
I
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Another possible explanation for the exaggerated acid response to GRP in 
the DU patients Is failure of inhibitory control processes. As discussed 
previously, acid output measured in response to stimulation with GRP is the 
end product of stimulatory pathways through the action of gastrin and 
inhibitory pathways through the action of CCK and other hormones. To assess 
whether the inhibitory limb of acid secretion is functional it is possible to 
compare the maximal acid response to endogenous gastrin released by GRP 
with the maximal acid response to exogenous gastrin. If the inhibitory limb is 
functional the former will be a fraction of the latter. If on the other hand the
:inhibitory limb is non functional the two acid responses will approximate. This 
approach was adopted in this study to examine the mechanism of the
:lexaggerated acid response to GRP seen in ttie DU patients.
I
_    ________
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6.2. PATIENTS AND METHODS
status was determined by the urea breath test. The urea breath test
Acid output was assessed basally and in response to GRP infused at the 
following rates: 10,40,100 and 200 pmol.kg'^.h'^ each for 45 minutes. All but
'II
Ten H  pylori negative healthy volunteers (7 males), ten H pylori positive 
healthy volunteers (7 males), and ten H  pylori positive DU patients (7 males) 
were studied. The three groups were matched for age and body weight. 
Duodenal ulcer patients were asked to stop any antisecretory therapy at least 
four weeks prior to the secretory studies. None of the healthy volunteers was 1
■s
on any medication and none reported major gastrointestinal symptoms. H
'
pylori infection was confirmed in the DU patients by microscopic examination of 
antral biopsy, rapid urease test (CLO test- Delta W est Pty Ltd, Australia) on
antral biopsy and by urea breath test. In healthy volunteers, H pylori 1
was performed as previously described in chapter 4.
Assessment of Maximal Acid Response to GRP Stimulated Gastrin and to 
Exogenous Gastrin-17
All subjects reported at 09;00h following a 12 hour fast. The secretory 
studies were performed in an identical fashion to that described in chapter 4. I
4 of these subjects also had their maximum acid response to Gastrin-17
___________ . .     j
assessed on a separate day. Following a 45 minute basal collection, Gastrin- 
17 was administered intravenously at a rate of 2000 ng.kg"^ h“'l for 60 
minutes. Gastric juice was collected in 4x15 minute aliquots.
............
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Maximal acid response to pentagastrin was determined in a further 11 DU
patients who did not have any assessment of their GRP response.
GRP infusions were prepared as described in chapter 4. Pentagastrin was 
purchased from ICI (Cheshire, England). Gastrin-17 was purchased from 
Cambridge Research Biochemicals ( Cheshire, England).
The volume and pH of each gastric juice collection were recorded and its .8
1hydrogen ion concentration measured by titration with 0.1 M NaOH to pH 7 
using an autotitrator (Radiometer ETS 822).
Basal acid output was calculated by taking the mean of all three 15 min 
samples prior to GRP or pentagastrin infusion. Acid output for each GRP 
infusion rate was calculated by taking the mean of the second and third 15 min
i:
collections. Maximal acid output to exogenous gastrin stimulation was 
calculated by taking the mean of all four 15 minute collections during the 
infusion. I.
____  _ _____________  _ . . . .  . . . . .
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Gastrin was measured by radioimmunoassay as described in chapter 4.
Eradication of H  oviori
Following the above secretory studies, all 21 DU patients were treated with 
tripotassium dicitratobismuthate 120mg t.i.d., metronidazole 400mg t.i.d. and 
amoxycillin 500mg t.i.d. for 3 weeks. One month following completion of this
therapy their urea breath test was repeated to determine H pylori status.
At one year post treatment GRP stimulated acid output was re-assessed in 
the ten DU patients. Pre-treatment, seven of these had had the prolonged 
GRP assessment as well as their maximal acid response to Gastrin-17 
assessed and therefore they had these same tests again at this point. At this
time point, however, the 200pmol.kg”8 h ”'* infusion rate of GRP was omitted as 
it had become apparent that the maximal response occurred at lower doses. 
The 11 additional DU patients who had only had a pentagastrin test pre­
treatment each had this repeated at one year post-treatment. Each patient 
having secretory tests at one year post-treatment also had a repeat urea 
breath test at this time to exclude re-infection.
Analysis
Vmax was estimated by fitting the data to a Langmuir model in which Vmax 
was the primary parameter of interest. This was appropriate in 33 out of the 40
EgI
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cases (82.5%). In the remaining 7 cases the acid level increased and then 
decreased with increasing doses of GRP and the maximal acid output was 
therefore estimated by inspection.
Statistics
Statistical analysis of unpaired data was performed using the Mann- 
Whitney U test and of paired data using the Wilcoxon test. A  'p' value of <0.05 
was taken as significant.
The study was approved by the Western Infirmary ethical committee.
:
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6.3. RESULTS
The repeat urea breath test at one month after completion of the triple 
anti-H pylori therapy indicated eradication of the infection in all DU patients. 
All 21 DU patients who were re-examined at one year post-eradication therapy 
remained free of the infection.
Maximal Acid Output to Exogenous Gastrin in DU Patients Before and One 
Year Following Eradication of H pylori
The median maximal acid output to exogenous gastrin in the 20 H pylori 
positive DU patients pre-treatment was 42mmol/h (range: 21-64). This was 
unchanged in the 18 patients re-examined at one year post-eradication, being 
38.5mmol/h (range: 22-63)(Fig.6.1.).
Maximal Acid Output to GRP
The median maximal acid output (mmol/h) to GRP was higher in the H  
pylori positive (20, range 5.5-35.9) versus negative healthy volunteers (6.4, 
range 3.6-8.6) (p<0.005)(Figs.6.2.,6.3.). The median value in the H pylori 
positive DU patients (39.2, range 24.6-54.7) was higher than both the H pylori
I
negative healthy volunteers (p<0.0002) and H pylori positive healthy 
volunteers (p<0.001). At one year post-eradication of H py/or/the median value 
in the DU patients had fallen to 7.9 (range: 4.1-22.6)(p<0.006 versus pre-
Maximal Acid Output 
(mmol/h) to Exogenous 
Gastrin
•i
I
60
50 “
t U r
30
20
One year post-Pre-
Î
S
Î
eradication eradication
FIG. {6.1.1
Maximal acid output to exogenous gastrin in the 18 DU patients examined 
before and one year following eradication of H pylori. Eleven of the patients 
were examined following pentagastrin and seven following Gastrin-17. The 
median values are indicated by horizontal lines.
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FIG. (6.2.)
Acid output in response to increasing doses of GRP in H  pylori negative 
healthy volunteers (n= 10), H  pylori positive healthy volunteers (n= 10), and 
DU patients (n= 10) before and one year following eradication of H pylori. The 
values are medians-
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Calculatetj maximal acid output to GRP stimulation in the various groups of 
subjects studied ( #  indicates H  pylori positive). The H  pylori positive healthy 
volunteers are higher than the H pylori negative volunteers (p<0.005). The H  
pylori positive DU patients are higher than all other groups (p<0.001) but 
became similar to the H  pylori negative healthy volunteers at one year post 
eradication.
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eradication) which was equivalent to that of the H pylori negative healthy 
volunteers. The maximal acid response to GRP stimulation in the infected DU 
patients and healthy volunteers occurred at approximately 1 0 0 pmol.kg"'l.h-1 ,
compared with 40pmol.kg-1.h"1 in the H pylori negative healthy volunteers or 
DU patients post-eradication. (Fig.6.2.).
Maximal Acid Output to GRP Versus Exogenous Gastrin-17
In the subjects described immediately above the median maximal acid 
output to exogenous Gastrin-17 was similar in the H  pylori negative (25.6, 
range 18-51.6) and positive (30.8, range 22.1-40.1) healthy volunteers 
(fig.6.4.). The median value in the DU patients was 43.0 (range: 36-58.5) 
which was higher than that of the other two groups (p<0.01). The value in the 
DU patients was unchanged at one year following eradication of H  pylori 
(median = 38; range: 32-63).
In the H pylori negative healthy volunteers the median value for the 
maximal acid response to GRP as a proportion of maximal acid output to 
exogenous Gastrin-17 was 27% (range: 9% -38%)(Fig.6.5.). The corresponding 
value was higher in the H  pylori positive healthy volunteers at 70% (range: 
25% -91% )(p<0.005). The value in the DU patients was 83% (range: 50% -97% ) 
which was higher than the H pylori negative healthy volunteers (p<0.001) but 
not significantly different from the H pylori positive healthy volunteers. At one
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FIG. (6.4.)
Maximal acid output to Gastrin-17 in the subjects from the various groups who 
also had their maximal response to GRP assessed ( #  indicates H pylori 
positive). The DU patients examined before and one year post H pylori 
eradication are identified by continuous lines. The H  pylori positive DU patients 
were higher than the healthy volunteers with and without H  pylori (p<0.01 for 
both) and were unchanged at one year post eradication.
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FIG. (6.5.)
Maxima! acid output to GRP as a percentage of maximal acid output to 
Gastrin-17 in H pylori negative healthy volunteers, H pylori positive healthy 
volunteers, and DU patients before and following eradication of H pylori (joined 
by continuous lines)( #  indicates H pylori positive). The values are similar in 
the H pylori positive healthy volunteers and DU patients and both higher than 
the H pylori negative healthy volunteers or DU patients at one year post 
eradication. '
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year post-eradication the value In the DU patients had fallen to 21% (range: 
16%-36%)(p<0.001 versus pre-eradication) which was similar to the value in 
the H  pylori negative healthy volunteers.
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6.4. DISCUSSION
In the present study we examined the effect of eradicating H pylori on the 
parietal cell mass in the DU patients. In some patients this was assessed using 
supramaximal doses of Gastrin-17 and in others using pentagastrin. These two 
methods have been shown to be equivalent in assessing maximal acid 
response to exogenous gastrin (140). DU patients are known to have a large 
parietal cell mass with their maximal acid response to pentagastrin being 1.5 to 
2 times higher than that of healthy controls (77). It is possible that this 
increased parietal cell mass is due to long-term trophic effects of H pylori 
induced hypergastrinaemia. However, we found no reduction in maximal acid 
response to exogenous gastrin at one year post-eradication. This is consistent 
with other studies which found no change at earlier time points following 
eradication therapy (98,111,116), and also with the one previous study which 
re-examined patients at one year post eradication (141). Following curative 
resection of gastrinomas, the increased parietal cell mass caused by the 
trophic effect of the hypergastrinaemia resolves within 3-6 months (137) and 
therefore one would expect to see resolution within the 12  month period 
assessed in our study. However, this does not completely exclude a role for H  
pylori induced hypergastrinaemia in contributing to the increased parietal ceil 
mass in DU patients. It is now recognised that the infection is usually acquired
1previous studies by demonstrating that the reason for the maximal acid 
response to GRP/bombesin approximating to that of exogenous gastrin was
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at an early age (142) and it is possible that exposure to hypergastrinaemia at
" iearly stages of development may have irreversible consequences.
In the present studies we were able to investigate the relationship 
between the maximal response to GRP and the maximal response to 
exogenous gastrin in the various groups studied. In H pylori positive DU 
patients the maximal acid response to GRP stimulated gastrin was 83% of that
to exogenous gastrin. This is consistent with 3 previous studies with bombesin ||
I;in DU patients which reported the maximal response to that peptide to be
■
between 80% and 100% of that to exogenous gastrin (133,143,144). In the H  
pylori positive healthy volunteers the maximal acid response to GRP was 70%  
of that to exogenous gastrin which was not significantly different from the DU 
patients. However the value in the H pylori negative healthy volunteers was 
markedly lower at 27%. Two previous studies have examined the maximal acid 
response to bombesin in healthy volunteers and both found it to be 
approximately 50% of that achieved with exogenous gastrin (133,145). The 
value of 50% in these previous studies in healthy volunteers is equivalent to Iour value when we combine our H pylori positive and negative healthy 
volunteers and is consistent with a proportion of those previously studied
S'i":
having H  pylori infection. In the present study we were able to extend the
I 
■
£: 
I
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related to H pylori In that the abnormality fully resolved following eradication of 
the infection.
The fact that H pylori infection causes the maximal acid response to GRP 
to approach the maximal acid secretory response to exogenous gastrin may 
provide an insight into the pathophysiological basis of the hypersecretory 
response. GRP stimulates the G cells to release gastrin and this in turn 
stimulates the parietal cells, directly or via histamine release from ECL cells, to 
secrete acid (130,143). However GRP also activates neuroendocrine pathways 
which exert inhibitory control on gastric secretion. It does this by stimulating
'■'"I
the release of a range of neuropeptides (including CCK, secretin, gastric 
inhibitory peptide, vasoactive intestinal peptide, neurotensin and
enteroglucagon) (128,133,146) which inhibit the acid response both at the 
level of gastrin release and acid response to gastrin stimulation (147-153). The 
activation of the CCK mediated inhibitory control by GRP/bombesin is 
demonstrated by the fact that the administration of the CCK A receptor 
antagonist to healthy human volunteers increases their gastrin and acid 
response to GRP/bombesin by 50% (154). The inhibitory neuropeptides which 
are released in response to GRP stimulation are thought to exert their 
inhibitory influence via stimulating the release of somatostatin from D cells 
which acts in a paracrine fashion on the G cells and parietal and/or ECL cells 
(155-163). However, in the case of secretin the inhibitory response is thought
 : _
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to be partly mediated via prostaglandin release (164). In some animals GRP 
also exerts inhibitory control directly on the stomach as well as via the central 
nervous system, but the importance of these pathways in man has not been 
defined (165,166). The administration of GRP therefore simultaneously 
activates these stimulatory and inhibitory control pathways of acid secretion 
and a likely explanation for the exaggerated response to GRP stimulation 
Induced by H  pylori is impairment of the inhibitory control. Strong evidence in 
favour of this is the finding that increasing doses of GRP allowed one to attain 
an acid response almost equivalent to the maximal secretory capacity in H  
py/or/positive individuals whereas only 27% of the maximal response could be 
achieved in uninfected controls. H  pylori infection has been shown to induce a 
reduction in immunoreactive somatostatin concentrations and somatostatin 
mRNA expression in the gastric mucosa (112,113) and this is consistent with 
the inhibitory control being disrupted at the level of somatostatin.
Our own unit in Glasgow and others have previously looked at the effect of 
H pylori on the inhibition of peptone stimulated gastrin and acid induced by 
intragastric acid (107,108,167). These studies found no defect in this control 
except for the one prolonged study in which impairment was seen in the 
second and third hour of intragastric acid and peptone infusion (167). A  normal 
response to inhibitory control exerted by intragastric acid does not preclude 
impaired inhibitory control mediated by the various intestinal hormones
1 S.'tzLL!             _ _ _ _ _ __ ____
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stimulated by GRP. Acid in the stomach can inhibit gastrin release by directly 
blocking the stimulatory effects of amino acids and amines on antral G cells 
(168,169). in contrast the inhibitory control exerted by the intestinal inhibitory 
hormones is indirect being mediated via somatostatin release.
In the studies presented in chapter (5) we found that GRP stimulated acid 
output in the H pylori positive DU patients was twice that of the H pylori 
positive healthy volunteers. This could not be explained by the degree of 
hypergastrinaemia as it was similar in both groups. The increased acid 
response to gastrin in the H  pylori positive DU patients, however, may be 
explained by their increased parietal cell mass. The fact that GRP stimulated 
acid output in the DU patients returned to normal at one year following 
eradication of H pylori despite no resolution of the increased parietal cell mass 
may be explained by the return of the normal inhibitory control both at the level 
of gastrin release and of acid response to gastrin. The fact that the 
exaggerated gastrin response resolved before the exaggerated acid response 
to gastrin may be explained by differences in the mediation of the inhibitory 
control in the antral and oxyntic mucosae (153).
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It could be argued that the more exaggerated acid response in the DU 
patients compared with the H pylori positive healthy volunteers, was related to 
rebound hypersecretion following the withdrawal of their acid inhibitory 
therapy. This is indeed a valid point and one which will have to be addressed. 
The studies presented in chapter (7) will attempt to answer this question.
W e showed in chapter (5) that the increased basal acid output which is 
characteristic of DU patients (83) also fully resolved following eradication of H  
pylori infection. Moss and Calam have also recently reported a 65% fall in 
basal acid output following eradication of the infection in their DU patients 
(111). The cause of the increased basal acid output in the DU patients is 
unclear but is likely to be due to H  pylori impairing the tonic inhibitory control of 
the large parietal cell mass characteristic of the DU patients (77).
Our findings of the effect of H pylori on the control of gastric secretion are 
likely to be relevant to the mechanism by which H pylori predisposes to 
duodenal ulceration. As already discussed the exaggerated response to GRP 
caused by H pylori is likely to be due to failure of inhibitory control exerted by 
neuropeptides mainly released from the duodenum and intestine. This 
inhibitory control is likely to serve as a means by which the duodenum and 
intestine can protect itself from excess exposure to acid delivered from the 
stomach. Failure of this protective feedback control of acid secretion by the
ii-ii_______________________________________________________________________________________________________   .
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duodenum is therefore a likely explanation for the mechanism by which H
■pylori predisposes to DU.
In 1977, prior to the recognition of H pylori, Malagelada et al performed 
elaborate studies of meal stimulated acid secretion in DU patients and healthy 
volunteers (170). These studies differed from most previous or subsequent 
studies of meal-stimulated acid secretion by the fact that they did not artificially 
elevate intragastric pH and thus interfere with the physiological response to 
the meal. They found that the ulcer patients had inappropriately prolonged 
acid response and increased rate of acid delivery into the duodenum following Ithe meal. The gastrin response was similar in the two groups. They concluded
:that this was most likely due to failure of the duodenal regulatory mechanisms 
that simultaneously control acid secretion and acid emptying. Their findings 
are consistent with our present finding of impaired inhibitory control of the acid 
response to gastrin in the DU patients which is fully reversed following 
eradication of H pylori
Our findings may also explain why H pylori leads to duodenal ulceration in Ionly a proportion of those carrying the infection. Those who develop duodenal 
ulceration are known to have a greater parietal cell mass and maximal acid 
secretory capacity (77). The H  py/or/-induced loss of inhibitory control in a 
subject with a large gastric acid secretory capacity is likely to be more injurious
■as^  _
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to the duodenum than the loss of control in a subject with a normal or small 
secretory capacity. The development of the clinical disease may therefore be 
explained largely by the combination of the acquired factor i.e. H pylon- 
induced loss of inhibitory control plus the genetic factor i.e. large parietal cell 
mass.
a-.    . _ . .   . .
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CHAPTER SEVEN
THE EFFECT OF RANITIDINE TREATMENT 
ON BASAL AND GRP STIMULATED GASTRIN 
AND ACID SECRETION IN HEALTHY 
VOLUNTEERS
__
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7.1. INTRODUCTION ■ .as
H2 receptor antagonists are valuable agents for the healing of duodenal 
and gastric ulcers and for relieving the symptoms associated with these 
conditions. However, a proportion of patients treated with these acid 
suppressive drugs experience a rapid resurgence of dyspeptic symptoms on 
discontinuing therapy. The recurrence of dyspeptic symptoms may simply be
'a#
due to the restitution of previous levels of acid secretion. However, another 
possible explanation of the early and marked resurgence of dyspeptic 
symptoms is that it is related to rebound acid hypersecretion.
W e have demonstrated in chapter five that H  pylori positive DU patients 
have a sixfold increase in their GRP stimulated acid secretion compared to H  
pylori negative healthy volunteers. W e proceeded to examine the mechanism I'of this exaggerated acid response to GRP in chapter six and our findings are 
consistent with H pylori disrupting the inhibitory pathways controlling acid 
secretion. The DU patients differed from the healthy volunteers in one very 
important aspect in that DU patients had been exposed to acid inhibitory 
therapy. The effect of this form of therapy on the regulatory pathways 
controlling acid secretion remain largely unknown. Although all our DU
■I
Î
patients were studied at least four weeks following discontinuation of acid
■‘3
suppressive therapy, we were concerned that at least part of this exaggerated
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acid response to GRP may in fact be due to the phenomenon of rebound acid 
hypersecretion.
Most of the early studies which examined acid secretion following 
withdrawal of H2 antagonists measured acid output in response to 
supraphysiological doses of histamine or pentagastrin and found no evidence 
of rebound hypersecretion (171-175). However, several more recent studies 
have used other methods of determining acid secretion and have reported the 
presence of significant rebound hypersecretion. In 1986, Frislid et al found that 
gastric acid secretion in response to a simulated meal in healthy volunteers 
was increased by more than 30% when examined 60 hours after completing a 
four week course of ranitidine ISOmg b.d. (176). In 1989, Fullarton et al 
studied nocturnal acid output before and two days following a four week 
course of nizatidine 300mg nocte in patients with healed duodenal ulcers 
(177). Before commencing treatment the median acid output was 
39.4mmol/10h and this increased to 74.1 mmol/1 Oh after treatment, 
representing a median increase of 77%. In 1991 Nwokolo et al reported an 
increase in nocturnal intragastric acidity one day after completing a twenty- 
eight day courses of either ranitidine, cimetidine or nizatidine in healthy 
volunteers (178). They also observed increased day-time intragastric acidity 
following the ranitidine therapy. In 1992, Kummer et al studied nocturnal acid 
output following a six week course of ranitidine 300mg nocte in patients with
_______________
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active duodenal ulcers (179). On the third day after stopping treatment, 10 
hour nocturnal acid output was 86.2 mmol compared with 54.7 mmol before 
treatment, representing a mean increase of 58%. In a similar study Fullarton et 
al observed a 44% increase in nocturnal acid output following ranitidine (180). 
These recent studies indicate rebound acid hypersecretion is evident when 
studied by tests which do not over-ride the normal regulatory controls of acid 
secretion as occurs when measuring maximal acid output.
As we have demonstrated in the previous chapters, GRP has proved to be 
a useful stimulus of gastric secretory function. In the present study we 
employed the GRP test to study the phenomenon of rebound acid 
hypersecretion following a two month course of a commonly prescribed H2 
antagonist (ranitidine). In view of the fact that H pylori alters the regulation of 
gastric acid secretion we have studied subjects with and without the infection.
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swallowed and secretory studies were performed as described in chapter four. 
Three 15 minute collections were obtained basally. An intravenous infusion of 
GRP was then started at a rate of 40pmol.kg \h   ^ and continued for 45 minutes 
during which a further three 15 minute collections of gastric juice were 
obtained. Blood samples were collected every 15 minutes for gastrin 
determination and the plasma stored at -20 °C.
7.2. SUBJECTS AND METHODS
Ten H pylori negative (8  males) and ten H pylori positive (8  males) healthy 
volunteers were studied. All subjects were matched for age and body weight 
(mean age for H pylori negative subjects = 29, range; 18-50; mean age for H  
pylori positive subjects = 30, range: 18-56). None had ever been exposed to 
acid inhibitory therapy and none had consulted their doctor with chronic 
dyspeptic symptoms. H pylori status was confirmed in each subject within 2 
weeks of entry to the study by the urea breath test.
Secretory Studies
W
All subjects had their basal and GRP stimulated gastrin and acid output 
measured within 2 days prior to starting ranitidine therapy. For this the 3subjects reported at 09:00h following a 12 hour fast. A  nasogastric tube was
I
I
i
3
3#
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Following their pre-treatment secretory tests the subjects were then given a 
pack containing 60 ranitidine (Zantac) tablets 300mg each. They were
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Basal acid output was calculated by taking the mean of all three 15 minute 
samples prior to GRP infusion. Acid output in response to GRP infusion was 
calculated by taking the mean of the second and third 15 minute collections.
i
IïVinstructed to take one 300mg tablet at 22:00h each night for the following 60
Ïdays. Compliance with the treatment was ensured by regular reminder phone 
calls and by pill counting at the end of the study.
?
The secretory studies described above were repeated in an identical 
fashion sixty hours and ten days after the last ranitidine dose. In three patients 
the secretory studies were performed again 17 days after stopping ranitidine.
i
Gastrin was measured by radioimmunoassay using antiserum R98 which 
has a sensitivity of 5ng/l (102). It binds G17 and G34 with equimolar potency.
3The basal gastrin value for each subject was determined by taking the mean of 
the three samples obtained prior to GRP infusion. The gastrin value in 
response to GRP infusion was determined by taking the mean of the two 
values at 30 and 45 minutes of the infusion. i
i
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The study was approved by the Western Infirmary ethical committee and 
all subjects gave written consent for the study.
«
Statistics |3
Statistical analysis was performed for matched pairs using the Wilcoxon 
test with significance taken at the 5% level.
3i ' i  
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7.3. RESULTS
Compliance
Eighteen out of 20 subjects (9 in each group) completed the study with 
100% compliance with the ranitidine treatment. The remaining 2 subjects (both 
male) were excluded from the post-treatment studies on the basis of poor
3i
compliance with treatment as assessed by pill counts at the end of the study.
Basal acid output and gastrin concentrations 3
The median basal acid output of the 18 subjects pre-treatment was 3.3 
mmol/h (range: 0.5-11.5). Sixty hours post-treatment it increased to 6.9 mmol/h 
(range: 4.7-17.8) representing a median increase of 109% compared to pre- itreatment values (p<0.01). The basal acid output returned to pre-treatment
' 3
values by day 10 (median 4.8; range: 1.8-14.9)(Fig. 7.1.a&b). This increase in 
basal acid output was not accompanied by any change in the median plasma
1:
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FIG. 7.1
Basal acid output (mmol/h) in H pylori negative 
subjects (a) and H pylori positive subjects (b), pre, 
60 hours post and 10  days post ranitidine 
treatment.
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gastrin concentrations: pre-treatment = 33 ng/l, range: 15-105; 60 hours post­
treatment = 43 ng/l, range: 10-195; 10 days post-treatment = 43 ng/l, range: 
10-180 (Fig. 7.2.a&b).
Analysis of the subjects according to H pylori status showed that the 9
,
positive subjects had higher basal gastrin concentrations ( median = 35, range:
30-105) and higher basal acid output ( median = 4.5, range: 1.2-11.5) pre­
treatment than the uninfected subjects ( median gastrin = 20, range: 15-65; 
median basal acid output = 3.0, range: 0.5-4.6) ( p<0.05 for both). Both groups
( median = 137%, range: 4% -840%  for the negative subjects and median = 
96% range: 7% -587%  for the positive subjects). Neither group showed
I
I
::
I;
were similar with respect to the degree of rebound in their basal acid output I 
}
significant rebound in basal gastrin concentrations.
GRP stimulated acid output and gastrin concentrations
The median GRP stimulated acid output of the 18 subjects pre-treatment 
was 10.0 mmol/h (range: 4.6-29.8). Sixty hours post-treatment it increased to 
15.6 mmol/h (range: 11.7-36.6) representing a median increase of 6 8 %
I
compared to pre-treatment values (p<0.01). The median GRP stimulated acid
I
output fell to 12.4 mmol/h (range: 5.1-40.3) by day 10 but was still significantly 
higher than pre-treatment value (p<0.05)(Fig. 7.3. a&b). However, the 
difference represented only 9% and was due to 4 subjects whose acid outputs
____________________
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remained relatively high 10 days post treatment (6 .8 , 8.1, 7.1 and 29.8 pre­
treatment compared to 10.2, 14, 10.3 and 40.3 respectively 10 days post­
treatment). These 4 subjects were re-examined one week later (i.e. 17 days 
post-treatment) and their GRP stimulated acid outputs fell to 6.5, 7,9, 7.6 and 
30.3 respectively which was equivalent to their pre-treatment value. The 
increase in GRP stimulated acid output was not accompanied by any 
significant change in the GRP stimulated plasma gastrin concentrations: pre­
treatment = 83ng/l, range: 20-250; 60 hours post-treatment = 100, range: 30- 
225; 10 days post-treatment = 70, range: 25-250,(Fig. 7.4.a&b).
Analysis of the subjects according to H pylori status indicated that the 9 
positive subjects had higher GRP stimulated gastrin concentrations ( median = 
95, range; 55-250) and acid output ( median = 19.0, range: 9.0-29.8) pre- 
treatment than the uninfected subjects ( median gastrin = 45, range 20-135; 
median acid output = 7.8, range: 4 .6-10.9)(p<0.01 for both). The H  pylori 
negative subjects showed a higher percentage of rebound in their GRP 
stimulated acid output than the positive subjects ( median = 108%, range: 
50%-154% vs median = 56%, range: 23% - 74% respectively)(p<0.01). Neither 
group showed significant rebound in GRP stimulated gastrin concentrations.
.
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7.4. DISCUSSION
The present studies demonstrate that a standard two month course of 
ranitidine therapy is associated with marked rebound of both basal and GRP 
stimulated acid secretion in subjects with and without H pylori Infection. In the 
group as a whole, basal acid output increased by 109% and GRP stimulated 
acid output by 68% at sixty hours after stopping ranitidine therapy. This 
rebound acid hypersecretion largely resolved by day 10 post-treatment.
The finding of rebound basal acid hypersecretion is consistent with the 
three previous studies of nocturnal acid output reporting mean increases 
ranging from 44% to 77% following withdrawal of H2 antagonist therapy 
(1 7 7  179  18 0 ) Rebound acid output has not been studied previously following 
GRP stimulation but our results are in keeping with the report by Frislid et ai 
who observed rebound hypersecretion following a sham-meal (176). There is 
therefore now strong evidence that H2 antagonists produce rebound 
hypersecretion of both basal and stimulated acid output.
In the present study, we included subjects with and without H pylori 
infection. This was done as the infection has been shown to alter the normal 
regulation of gastrin release and acid secretion and could therefore modify 
rebound acid hypersecretion. H  pylori positive healthy volunteers have
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increased basai, meal-stimulated and GRP-stimulated serum gastrin 
concentrations compared with uninfected subjects (97,119). In addition, 
infected volunteers have a 1.5-2 fold increase in basal acid output and 2-3 fold 
increase in GRP stimulated acid output compared to controls. These 
disturbances in gastrin and acid secretion fully resolve following eradication of 
the organism. The H  pylori positive healthy volunteers included in the present 
study showed this previously reported increase in basal and GRP stimulated 
gastrin and acid output.
The percentage increase in basal acid output following discontinuation of 
ranitidine therapy was similar in H pylori positive and negative healthy 
volunteers. However, the percentage increase in GRP stimulated acid output 
was higher in the H pylori negative volunteers than in those with the infection. 
This may be explained by the fact that GRP stimulation in H pylori positive 
healthy volunteers produces an acid output which is equivalent to 
approximately 70% of their maximal acid output. Consequently, those with the 
infection only have the capacity to increase GRP stimulated acid secretion by 
approximately 50% which approximates to the rise noted in the present study. 
In contrast, GRP stimulation in subjects without H pylori produces an acid 
response of only about 25% of their maximal acid secreting capacity and they 
therefore have a greater reserve in which to increase their acid output.
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The mechanism of the rebound acid hypersecretion following H2 antagonist 
therapy is unclear. It cannot be explained by an increase in the parietal cell 
mass as numerous previous studies have shown no change in maximal acid 
output to stimulation with pentagastrin or histamine following treatment with H2 
antagonists (171-175). In addition, it does not appear to be directly mediated 
by increased gastrin release as neither the basal or GRP stimulated acid 
rebound were associated with any rebound increase in gastrin levels. In 
keeping with our findings, previous studies of rebound hypersecretion have 
also found no evidence of rebound hypergastrinaemia (172,173,177,178,180). 
In addition, the rebound hypersecretion cannot be explained by increased 
parietal cell sensitivity to gastrin as studies by Aadland and Berstad (1974) 
found this unaltered in DU patients or healthy volunteers when examined 60 
hours and 84 hours after completing a 6  week course of cimetidine (175).
There is some evidence that rebound acid hypersecretion following H2 
antagonist therapy may be explained by an increased sensitivity to histamine. 
Aadland and Berstad examined acid secretion in response to submaximal and 
supramaximal doses of histamine in healthy volunteers before and following 
four weeks treatment with cimetidine (175). They found that the acid response 
to the low dose of histamine increased significantly due to an increased 
parietal cell sensitivity to the amine. Jones et al studied acid secretion in 
patients with healed duodenal ulcers before and after three months treatment
I"
I
I
I
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with ranitidine ISOmg nocte (181). Following withdrawal of treatment , they 
found an increased acid response to stimulation with the Hz agonist, 
impromidine, and also an increased acid inhibitory response to the Hz 
antagonist, ranitidine. This was again interpreted as showing an enhanced 
sensitivity of the Hz receptor possibly due to an increase in the number of Hz 
receptors i.e. up-regulation.
be considered. Acid secretion basally and in response to a meal or GRP
'I
Other possible explanations for the rebound hypersecretion also need to
:
depends upon the interaction of both stimulatory and inhibitory controls. The 
rebound hypersecretion observed by each of these methods could therefore 
be explained by down-regulation of the inhibitory controls especially those 
which are activated by acid in the stomach or duodenum. The inhibitory control 
of acid secretion by the oxyntic mucosa is partly mediated via the release of 
somatostatin from fundic mucosal D cells and acid suppression by omeprazole
%reduces somatostatin mRNA in the fundic mucosa of animals (182).
The present studies clearly demonstrate substantial rebound acid 
hypersecretion following discontinuation of Hz antagonist therapy. The clinical 
significance of this phenomenon with respect to rapid resurgence of symptoms 
remains to be determined. It has also been shown that the rebound in acid 
secretion largely resolves within two weeks of discontinuing therapy in healthy
i
 ^ ' :      _
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volunteers. This suggests that the four week interval off treatment after which 
our DU patients were studied in the previous chapters was probably adequate 
to avoid any false increase in their acid outputs caused by rebound. This 
however does not exclude the possibility that long-term acid inhibition, which 
most DU patients are under, may in fact be contributing to their ulcer diathesis 
by damaging the inhibitory control pathways in a similar fashion to H  pylori 
infection.
!
I
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CHAPTER EIGHT
THE EFFECT OF H PYLORI INFECTION ON
■Ï
• j
" Ï
i
Î
I
GRP STIMULATED GASTRIN AND ACID
SECRETION IN NUD PATIENTS
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8.1. INTRODUCTION
Dyspepsia is a very common disorder with a prevaience of 30-40%  in the
'è
general population of the UK (183,184). The disorder accounts for 10-20% of
i'GP consultations (185) and 30% of hospital gastroenterology referrals (186).
In over 50% of dyspeptic patients upper Gl investigations are non-definitive 
and these patients fall into the category of non-ulcer dyspepsia 
(NUD)(187,188). Consequently, NUD is the commonest diagnosis in patients
1
presenting with dyspepsia.
€
!The recent recognition of the pathogenic role of H pylori infection in 
duodenal ulcer (DU) disease is transforming the management of that condition 
and removing the need for long-term treatment with expensive acid inhibitory
3therapy. The cause of NUD remains unknown but there is considerable 
interest in its relationship to DU disease and in the possible role that H pylori
■iinfection may have in the condition.
IOur own results presented in chapter five have shown that H  pylori positive 
DU patients have a 6 -fold increase in acid secretion in response to stimulation
aby GRP, when compared with H pylori negative healthy volunteers. GRP 
stimulated acid secretion is also increased in healthy volunteers with the
'I;
infection but their median output is only 3 times that of H  pylori negative
Ï
I
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healthy volunteers. The very marked increase In acid secretion in DU patients 
is likely to represent a key pathophysiological defect underlying their DU 
disease. W e also showed that the hypersecretion of acid in both H pylori 
positive DU patients and healthy volunteers is entirely due to the infection as 
it fully resolves following eradication of the organism.
This recognition of disturbed gastric secretory function caused by H pylori 
and associated with DU disease may be helpful in investigating the 
pathogenesis of NUD. In particular the assessment of GRP stimulated acid 
secretion may provide a means of identifying NUD subjects with a similar 
disturbance of gastric function as DU patients and which could be reversed by 
eradication of their H pylori infection.
The aim of the present study was to determine whether the underlying 
disturbance of acid secretion characteristic of DU disease is also present in a 
proportion of H pylori positive NUD patients.
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8,2- PATIENTS AND METHODS
Twenty five H pylori positive NUD patients (16 males) were studied. Their 
median age was 35 years (range: 18-59). The patients were recruited 
consecutively from our Gl outpatient clinic and all fulfilled the following three 
criteria: (1) a six month or longer history of dyspepsia. This consisted of upper 
abdominal or retrosternal pain, discomfort, heartburn, nausea, vomiting, or 
other symptom considered referable to the proximal alimentary tract, and 
unrelated to exercise. (2) No macroscopic abnormality of the upper Gl tract 
demonstrable despite at least two upper Gl investigations including one 
endoscopy. (3) Evidence of H pylori infection as confirmed by microscopic 
examination of antral biopsies, rapid urease test (CLO test) on antral biopsy
and urea breath test.
The above NUD patients were compared to three groups of subjects: 25 H  
pylori negative healthy volunteers (17 males), 25 H pylori positive healthy 
volunteers ( 1 7  males), and 25 H pylori positive DU patients (17 males). The 
DU patients had all been confirmed to have an active ulcer by endoscopic 
examination within the previous 12 months. All groups were matched for age 
and body weight.
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NUD and DU patients were asked to stop any antisecretory therapy at least 
four weeks prior to the secretory studies. None of the healthy volunteers was 
on any medication and none had consulted the medical profession on account 
of dyspepsia. H pylori infection in the DU patients was confirmed as for the 
NUD patients. In the healthy volunteers, H pylori status was determined by the
urea breath test.
Secretory Studies
All subjects reported at 09:00h following a 12 hour fast. The GRP test was 
performed in an identical fashion to that described in chapter four. Three 15 
minute collections were obtained basally and at each of the following rates of 
I.V. infusion of GRP: 10 and 40pmol.kg'\h"\ Gastrin and acid output were 
measured as described previously.
Statistics
Statistical analysis was performed using the Mann-Whitney U test. A  'p' 
value of <0.05 was taken as significant.
In the NUD patients linear regression analysis was performed to look for 
correlation between acid output and age and duration of dyspeptic symptoms.
The study was approved by the Western Infirmary ethical committee.
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8.3. RESULTS
Basal Gastrin
The basal gastrin concentration (ng/l) was similar in the H  pylori positive 
healthy volunteers (median = 45, range: 10-90), H pylori positive NUD patients 
(60, range: 25-270), and H  py/or/positive DU patients (60, range: 22-175) and 
all were higher than the H  pylori negative healthy volunteers (32, range: 15-50) 
(p< 0.005 for all three)(Fig.8.1.).
Gastrin Response to GRP
At the GRP infusion rate of 40pmol.kg Vh'  ^ the median gastrin 
concentration (ng/l) was increased to a similar level in the H  pylori positive 
healthy volunteers (238, range: 38-563), H  pylori positive NUD patients (225, 
range: 55-700), and H  pylori positive DU patients (255, range: 90-600) and 
each was higher than that of the H pylori negative healthy volunteers (70, 
range: 28-157)(p< 0.002 for each)(Fig.8.3.).
The gastrin response in the four groups of subjects at the GRP infusion 
rate of lOpmol.kg Vh“^ showed the same pattern of response to that seen in 
response to GRP 40pmol.kg"\h \  W e chose to present the results of the 
individual data points for the 40pmol.kg \h'^ GRP rate as the gastrin levels 
stimulated by this are closer to those seen following a meal.
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FIG. (8.1.1
Basal gastrin concentrations in the four groups of subjects studied. The H  
pylori positive NUD patients were higher than the H pylori negative healthy 
volunteers (p<0.002) and similar to the H pylori positive healthy volunteers and 
DU patients.
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Fig. (8.2.1
Basal acid output in the four groups of subjects studied. The H pylori positive 
NUD patients were higher than the H pylori negative healthy volunteers 
(p<0.01) and lower than the DU patients (p<0.03), but not different from the H  
pylori positive healthy volunteers.
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Serum gastrin concentrations in response to stimulation with gastrin releasing 
peptide (40pmol.kg*Vh*^) in the four groups studied. The H pylori positive NUD 
patients were higher than the H pylori negative healthy volunteers (p<0.002) 
and similar to the H  pylori positive healthy volunteers and DU patients.
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:Basal Acid Secretion
The median basal acid output (mmol/h) was higher in the H pylori positive 
healthy volunteers (2.9, range: 0.5-13.3)(p<0.05) and H pylori positive NUD 
patients (4.8, range: 0.3-16.7)(p<0.01) compared to the H pylori negative
■|healthy volunteers (1.8, range: 0.5-7.9). However, there was no statistically 
significant difference between the basal acid output in the H pylori positive 
healthy volunteers and NUD patients (p=0.2). The median basal acid output in 
the H pylori positive DU patients was 6 .6 mmol/h (range: 2.6-25.8) and was
significantly higher than that of the H pylori positive NUD patients (p<0.03), H
i:pylori positive healthy volunteers (p<0.001), and H pylori negative healthy
volunteers (p<0.0001)(Fig.8.2.).
I
Acid Response to GRP
At GRP 40pmol.kg'\h"^ the median acid output (mmol/h) in the H pylori 
positive healthy volunteers (19.0, range: 1.0-38.3) was approximately 3 times Ithat of the H pylori negative healthy volunteers (6.3, range: 2.8-20.9)(p<0.001).
- ■
At this infusion rate the median acid output in the H pylori positive NUD
■
patients was 29.6 (range: 5.2-46.5) which was approximately 5 times that of 
the H pylori negative healthy volunteers (p<0.0001) and 1.5 times that of the H  
pylori positive healthy volunteers (p<0.001). The median acid output in the H  
py/or/positive DU patients was 39.1 (range: 17.9-64) which was approximately 
6  times that of the H pylori negative healthy volunteers (p<0.0001) and twice
I
 :_________________________
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that of the H pylori positive healthy volunteers (p<0.005). Acid output was 
significantly higher in the H pylori positive DU patients compared to the H  
py/or/positive NUD patients (p<0.001)(Fig.8.4.).
Acid outputs in response to 10 pmol.kg \h   ^ of GRP followed the same 
pattern in the four groups as those obtained in response to 40 pm ol.kg '\h '\
In the NUD patients linear regression analysis showed that there was no 
correlation between acid output and either age (r=0.2, p=0.87), or duration of 
dyspeptic symptoms (r=0.1, p=0.9).
 :  .    .........
Acid Output (mmol/h)
70
60 -
50 H
40
30 -
20
10
0
# #
gO pogo8g
o o H o q S o
# # # # # # #
#
# # #e
# #.1.
1 ................T . ............- 1 1
HP -ve HP -Kve HP 4-ve HP 4-veHealthy Healthy N.U.D. D.U,Volunteers Volunteers Patients Patients
I
:î
F W M J
Acid output in response to stimulation with gastrin releasing peptide 
(40pmol.kg \h'^). The acid output In the H pylori positive NUD patients was 
higher than the H pylori negative healthy volunteers (p<0.0001) and H pylori 
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H  pylori is now established as the major acquired factor in the
DU patients and healthy volunteers with the infection (96-101,132). The 
hypergastrinaemia is accompanied by a 3 fold increase in GRP stimulated acid 
output in infected healthy volunteers and a more marked 6  fold increase in DU
Both basal and GRP stimulated gastrin concentrations were increased to 
a similar extent in the NUD patients compared with H pylori positive healthy 
volunteers and DU patients. This confirms previous findings that the magnitude
8.4. DISCUSSION
pathogenesis of DU disease. The mechanism by which it predisposes to DU
disease is likely to be related at least in part to its effects on gastric acid
I
secretion. H  pylori increases basai, meai stimuiated and GRP stimuiated
gastrin concentrations and the magnitude of the hypergastrinaemia is similar in
' I
patients. DU patients with H pylori thus resemble infected healthy volunteers in
having a similarly exaggerated gastrin response but differ from them in 
producing twice as much acid for equivalent gastrin levels basally and during
■iGRP stimulation. In the present study we have studied gastric function in H  
pylori positive NUD patients to see whether a subgroup have a similar 
disturbance to DU patients.
of basal and stimulated hypergastrinaemia is similar in the presence of H  pylori
"M
■■'A
:
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infection regardless of whether the subject is healthy or has dyspeptic disease 
(97).
The basal acid output was significantly increased in the H pylori positive 
NUD patients compared to the H pylori negative healthy volunteers, but was 
also significantly less than in the DU patients. There was no statistically 
significant difference in basal acid output between the infected healthy 
volunteers and NUD patients, though there was a trend in favour of it being 
higher in the latter.
GRP stimulated acid output in the NUD patients was 5 times higher than 
the H pylori negative healthy volunteers but significantly lower than the H pylori 
posW e DU patients. The GRP stimulated acid output in the NUD patients was 
a ls | 60% higher than that of the H  pylori positive healthy volunteers. The 
median GRP stimulated acid output in the NUD patients thus fell half way 
between that of the H  pylori positive healthy volunteers and the H pylori 
positive DU patients. This could be explained by approximately half the NUD 
patients having GRP stimulated acid secretion similar to the DU patients and 
half having acid secretion similar to the H pylori positive healthy volunteers. 
Alternatively, it could be due to NUD patients having GRP stimulated acid 
output which falls between that of DU patients and infected healthy volunteers.
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The former explanation is the more likely as previous studies indicate that 
NUD is a heterogeneous condition (189).
The mechanism of the increased GRP stimulated acid secretion in the 
NUD patients was similar to that in the DU patients. The DU patients had a 
similar gastrin response to the infected healthy volunteers and thus their 
higher acid response was due to an increased acid response to gastrin during 
GRP stimulation. Likewise the NUD patients had the same gastrin response to 
GRP as the infected healthy volunteers and thus their higher acid output was 
again due to an increased acid response to gastrin during GRP stimulation.
The finding that a subgroup of H pylori positive NUD patients have a 
similar disturbance of gastric function to DU patients may be relevant to the 
underlying cause of their dyspeptic disease. It is well recognised that 
symptoms in DU patients correlate poorly with the presence of actual 
ulceration (190-194) and the pain is thus not simply due to the effect of excess 
acid on an active ulcer. The precise mechanism of pain in DU disease is 
unknown but is likely to be due to the interaction of excess acid secretion and 
inflammation of the gastroduodenal mucosa (195). This mechanism could also 
explain the pain in the NUD patients who have an exaggerated GRP 
stimulated acid response similar to the DU patients.
   _ _ . ifii;
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If a subgroup of H pylori positive NUD patients have a similar basis to their 
dyspeptic symptoms as DU patients then eradication of the infection is likely to 
benefit them in a similar way to DU patients. Such treatment would both lower 
their GRP stimulated acid secretion and resolve the inflammation of their 
mucosa. Previous studies of the value of eradicating H pylori in patients with 
NUD have produced conflicting results and this is consistent with the infection 
playing a role in only a subgroup of NUD patients (196-198). The challenge 
now is to find a means of identifying the subgroup of patients with NUD whose 
symptoms are secondary to their H pylori infection and who are therefore most 
likely to benefit from its eradication. Assessment of GRP stimulated acid 
secretion might provide a means of identifying such patients.
---------------------------------------- ---
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CHAPTER NINE
SUMMARY AND CONCLUSIONS
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H  pylori infection is the commonest chronic bacterial infection world-wide. It 
has been associated with a variety of upper gastrointestinal diseases including 
gastritis, duodenal and gastric ulcer disease, non ulcer dyspepsia and gastric 
carcinoma. The mechanism by which this common infection predisposes to 
these diseases remains poorly understood. The work carried out in this thesis 
has sought to explore the effect of the infection on gastric secretory function in 
man.
The first objective of the thesis was to develop a new approach to the study 
of gastrin mediated acid secretion without using food as the stimulus, thus 
avoiding all the technical difficulties and inaccuracies associated with this. This 
was achieved by using the substance gastrin releasing peptide (GRP). Acid 
secretion measured in response to intravenous infusion of GRP is the end 
product of the stimulatory and inhibitory mechanisms controlling acid secretion 
and reflects the combined functional response of the antrum and body of the 
stomach. It simulates the response to eating and represents a more 
physiological test of gastrin mediated acid secretion than most of the currently 
available tests of acid secretion. The reproducibility of the GRP test was 
assessed and was found to be highly reproducible for both gastrin and acid 
secretion. W e recommend the use of the GRP infusion rate of 
40 pmol.kg ^h"' as this was found to be the most reproducible for both gastrin 
and acid secretion. In addition the gastrin levels achieved in response to
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stimulation by this dose are comparable to those achieved in response to 
stimulation by a test meal.
Using this new and highly reproducible tool we proceeded to study acid 
secretion in a variety of subjects with and without H pylori infection. W e have 
shown that GRP stimulated acid secretion is increased six fold in DU patients 
with the infection compared to H pylori negative healthy volunteers (true 
normals). This exaggerated acid response is likely to represent a key 
pathophysiological defect which underlies DU disease. W e also showed that 
eradication of H  pylori infection leads to complete normalisation of basal and 
GRP stimulated gastrin and acid secretion in DU patients. The gastrin 
abnormality resolves within one month of eradication and the acid abnormality 
takes upto one year to fully resolve. These novel findings have shed 
considerable light on the pathophysiology of DU disease and the role of H  
pylori infection in it.
W e have also shown for the first time that GRP stimulated acid secretion is 
increased two to three fold in H  pylori positive healthy volunteers compared to 
true normals. This redefinition of true normality has allowed the clear 
separation of the duodenal ulcer diathesis without any overlap with normals. 
Since half the world’s population is colonised with H pylori infection, these 
findings will have to be taken Into account when designing future research
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projects on gastric function. The finding that H  pylori infection produces a two 
to three fold increase in acid secretion in the general population which 
resolves following eradication of the infection may also be of relevance to 
other dyspeptic disorders such as reflux disease.
W e proceeded to investigate the mechanism of the exaggerated acid 
response to GRP in DU patients and presented evidence compatible with this 
being due to impaired inhibitory control of acid secretion. This was shown by 
demonstrating that true normals achieve a small proportion of their maximal 
acid secretory capacity when stimulated with GRP compared to stimulation 
with exogenous gastrin and this is consistent with GRP activating an intact 
inhibitory pathway capable of attenuating the acid response to GRP. In 
contrast, DU patients achieve almost all their maximal acid secretory capacity 
in response to stimulation with GRP compared to stimulation with exogenous 
gastrin consistent with the inhibitory pathway being defective and incapable of 
attenuating the acid response to GRP.
The finding that eradication of H pylori infection did not alter the maximal 
acid secretory capacity of DU patients suggests that H  pylori does not play a 
part in determining this and that other factors such as the genetic makeup of 
the individual is probably involved. As such one might speculate that the 
individuals who are predisposed to developing DU disease are those who are
■ ' ' ' '   :    ... .
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I
born with a large parietal cell mass and who subsequently acquire H pylori
relevance to the understanding of DU disease as well as other upper Gl 
diseases which have been linked to H  pylori infection.
.1infection. This then damages their ability to attenuate and control the amount 
of acid secreted by the stomach in response to appropriate stimuli with a 
marked increase in the amount of acid delivered to the unprotected duodenal 
mucosa. Future research should now focus on the nature of the defect in the
■A"inhibitory control mechanisms caused by H pylori infection. This will be of
aï
W e proceeded to examine the effect of the most commonly prescribed 
medication for dyspepsia, i.e. ranitidine, on acid secretion in healthy 
volunteers with and without H  pylori infection. This was done to investigate 
whether treatment with H2 antagonists leads to rebound acid hypersecretion i
following withdrawal of therapy which could contribute to the exaggerated acid
response seen in DU patients. W e showed that a two month course of 
ranitidine leads to a doubling of basal acid output and a 6 8 % increase in GRP 
stimulated acid output two days after withdrawing treatment. This rebound acid 
hypersecretion is not associated with any significant change in gastrin 
concentrations and fully resolves within ten days of stopping ranitidine. All our 
DU patients were studied at least four weeks after stopping acid inhibitory 
therapy. However, DU patients are usually on this medication for much longer 
periods and the long-term effects of chronic suppression of acid secretion
s
:
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remain unknown. It is still possible that part of the exaggerated acid response 
seen in DU patients is due to rebound acid hypersecretion following acid 
suppressive therapy. This suggests albeit controversially that these drugs may 
be accentuating the DU diathesis and are contributing to the secretory 
abnormalities seen in DU patients. Our findings of significant rebound in both 
basal and GRP stimulated acid secretion offer an explanation for the common 
clinical problem of rapid resurgence of dyspeptic symptoms following 
discontinuation of acid suppressive therapy. Future work will now focus on the 
clinical aspects of this phenomenon by assessing in a double blind placebo 
controlled fashion the presence and severity of dyspeptic symptoms following 
discontinuation of acid suppressive therapy in healthy volunteers. W e will also 
proceed to investigate the mechanism of the rebound phenomenon by 
examining the effect of acid suppressive therapy on parietal cell sensitivity and 
on the acid inhibitory control mechanisms.
Finally, we used the GRP test to study acid secretion in patients with non 
ulcer dyspepsia (NUD) and H pylori infection. W e showed that NUD patients 
display a wide spectrum of acid secretion ranging from low to very high. A  
significant proportion of NUD patients showed an exaggerated acid response 
to GRP similar to DU patients i.e. they displayed the DU diathesis. This raises 
the exciting possibility that this group of NUD patients could be cured by 
eradication of their H pylori Infection. This hypothesis needs to be tested in a
 -   _ _.   .
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large double blind placebo controlled trial which will examine the value of 
eradication of the infection in NUD patients. W e have designed such a trial 
funded by the Medical Research Council and work has already started in our 
unit on this large project. Over the next three years new guidelines for the 
management of NUD patients will hopefully become available.
S
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